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Abstract	  Cis-­‐regulatory	  regions	  such	  as	  enhancers	  are	  associated	  with	  regulating	  transcription	  of	  target	  genes.	  Many	  of	  these	  regulatory	  regions	  are	  distally	  located	  over	  1kb	  away	  from	  their	  target	  promoter,	  and	  many	  studies	  been	  conducted	  to	  identify	  how	  enhancer	  and	  promoter	  regions	  are	  brought	  into	  proximity	  to	  allow	  interaction	  and	  initiation	  of	  transcription.	  Such	  research	  has	  identified	  protein	  complexes	  such	  as	  SAGA	  and	  ATCA,	  which	  bind	  to	  specific	  enhancers	  and	  promoters	  bringing	  them	  into	  close	  proximity.	  This	  study	  focuses	  on	  one	  unique	  subunit	  of	  the	  ATAC	  complex,	  zzz3.	  By	  knocking	  down	  expression	  of	  zzz3	  in	  zebrafish	  by	  morpholino	  injection,	  the	  role	  zzz3	  plays	  in	  development	  and	  phenotype	  can	  be	  determined.	  It	  was	  observed	  during	  this	  study	  that	  zzz3	  knockdown	  resulted	  in	  a	  bent	  tail	  and	  ventralisation	  of	  embryos,	  suggesting	  a	  potential	  role	  for	  this	  protein	  in	  the	  development	  of	  the	  floor	  plate	  and	  notochord.	  
	   7	  
	  
Introduction	  
Cis	  regulator	  regions	  Initiation	  of	  gene	  transcription	  is	  a	  complex	  system	  involving	  rearrangement	  of	  chromatin	  into	  a	  permissive	  state	  by	  histone	  modifications.	  This	  is	  followed	  by	  the	  recruitment	  of	  many	  transcription	  factors,	  and	  co-­‐activators	  to	  a	  gene’s	  promoter	  region	  before	  transcription	  via	  RNA	  polymerase	  II	  can	  occur.	  Transcription	  is	  often	  regulated	  by	  cis-­‐regulatory	  regions	  located	  in	  non-­‐coding	  regions	  of	  the	  DNA,	  including	  enhancers	  (associated	  with	  increased	  gene	  transcription)	  and	  insulators	  (protecting	  genes	  from	  transcription),	  located	  either	  within	  1Kb	  (proximal	  promoter	  elements)	  or	  >1Kb	  (distal	  elements)	  of	  the	  transcription	  start	  site	  (Krebs,	  A	  Thesis	  2010;	  Epstein.	  D	  2009).	  	  	  
Mutations	  within	  the	  cis-­‐	  regulatory	  regions	  of	  the	  human	  genome	  have	  been	  attributed	  to	  1-­‐2%	  of	  disease	  causing	  mutations	  and	  are	  responsible	  for	  conditions	  such	  as	  preaxial	  polydactyly,	  where	  a	  mutation	  in	  the	  upstream	  Sonic	  
hedgehog	  (Shh)	  enhancer	  results	  in	  extra	  digits	  forming	  during	  development.	  A	  mutation	  in	  the	  IRF6	  enhancer	  results	  in	  an	  increased	  risk	  of	  non-­‐syndromes	  cleft	  palate	  (Epstein.D	  2009).	  
Zebrafish	  Zebrafish	  (Danio	  rerio)	  are	  an	  established	  	  model	  organism	  for	  the	  study	  of	  human	  disease	  and	  embryonic	  development,	  becoming	  popular	  due	  to	  its	  ease	  of	  use,	  relatively	  low	  maintenance	  costs,	  ability	  to	  produce	  large	  quantities	  of	  embryos	  each	  mating,	  permitting	  semi	  high	  throughput	  screening	  assays	  (either	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pharmaceutical	  or	  genetic).	  Embryos	  are	  transparent	  and	  develop	  rapidly	  outside	  of	  the	  mother,	  removing	  the	  need	  to	  dispatch	  the	  mother	  (Fleming.A	  2007).	  	  Zebrafish	  have	  therefore	  been	  used	  in	  many	  studies	  and	  even	  as	  a	  model	  for	  studied	  in	  to	  the	  genetic	  basis	  for	  human	  diseases	  such	  as	  muscular	  dystrophy	  (Kawahara.G	  et	  al	  2010).	  Other	  groups	  have	  been	  investigating	  the	  genetics	  employed	  by	  zebrafish	  in	  heart	  regeneration	  after	  damage,	  to	  better	  understand	  mechanisms	  that	  could	  potentially	  be	  translated	  into	  treating	  human	  heart	  disease	  (Jopling	  et	  al	  2010).	  	  
Zebrafish	  have	  also	  proved	  indispensable	  in	  the	  search	  for	  enhancers	  and	  other	  cis-­‐regulatory	  regions.	  For	  example	  Müller.F	  et	  al	  1999,	  successfully	  mapped	  the	  
shh	  enhancer	  location	  and	  identified	  that	  the	  enhancer	  is	  split	  into	  3	  regions	  across	  two	  introns,	  as	  well	  as	  identifying	  in	  which	  tissues	  each	  enhancer	  region	  promotes	  shh	  expression,	  such	  as	  the	  notocord,	  and	  the	  floorplate.	  The	  identification	  of	  enhancer	  regions	  presents	  many	  challenges,	  predominantly	  due	  the	  promiscuity	  of	  enhancer	  interactions.	  Therefore,	  to	  aid	  discovery,	  screens	  of	  enhancer	  promoter	  constructs	  have	  been	  conducted.	  Zebrafish	  provide	  an	  excellent	  model	  for	  in	  vivo	  analysis	  for	  these	  constructs.	  With	  the	  advances	  in	  technology	  it	  has	  now	  become	  possible	  to	  map	  these	  construct	  in	  zebrafish	  in	  a	  high	  throughput	  manner	  (Gehrig.J	  et	  al	  2009).	  	  
Zebrafish	  are	  an	  essential	  model	  organism	  of	  developmental	  genetics	  and	  more	  recently	  emerged	  as	  models	  for	  human	  disease.	  Coupled	  with	  advances	  in	  technology,	  such	  as	  development	  of	  high	  throughput	  assays	  and	  specific	  gene	  knock	  down	  by	  morpholino	  oligonucleotides,	  the	  zebrafish	  provides	  a	  basis	  for	  many	  more	  genetic,	  developmental	  investigations.	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Morpholino	  (Mo)	  technology	  A	  key	  development	  in	  targeted	  gene	  knockdown	  in	  vivo	  was	  the	  development	  of	  Mo,	  chemically	  altered	  oligonucleotides	  with	  high	  affinity	  for	  mRNA.	  These	  inhibit	  mRNA	  translation	  in	  an	  RNaseH	  endonucleoase	  independent	  manner	  (Nasevicius.	  A	  &	  Stephen	  .C	  2000)	  via	  blocking	  the	  progression	  of	  the	  ribosome	  along	  the	  mRNA,	  in	  a	  similar	  mechanism	  to	  RNAi	  technology,	  or	  preventing	  proper	  mRNA	  splicing	  (Eisen	  and	  Smith	  2008;	  Bill.	  BR	  et	  al	  2008).	  Mo’s	  are	  chemically	  modified	  bases	  consisting	  of	  a	  six	  membered	  morpholino	  ring,	  instead	  of	  the	  standard	  ribose	  ring	  found	  in	  RNA,	  linked	  together	  to	  form	  oligonucleotides.	  This	  modification	  increases	  the	  stability	  of	  the	  oligonucleotides,	  and	  renders	  them	  resistant	  to	  nucleases.	  Another	  key	  feature	  of	  Mo	  oligonucleotides	  is	  that	  they	  do	  not	  possess	  a	  negatively	  charged	  backbone,	  unlike	  RNA	  and	  DNA.	  This	  means	  that	  nonspecific	  interactions	  are	  reduced	  and	  therefore	  Mo	  is	  likely	  to	  be	  less	  toxic	  to	  cells	  than	  RNAi	  (Eisen	  and	  Smith	  2008).	  
When	  designing	  Mo	  oligonucleotides,	  it	  is	  advised	  that	  the	  Mo	  is	  a	  maximum	  of	  around	  25	  bases	  long	  with	  no	  secondary	  structure,	  designed	  to	  be	  complementary	  for	  the	  target	  mRNA	  transcript.	  	  To	  ensure	  the	  effects	  observed	  after	  Mo	  injection	  are	  true	  findings	  it	  is	  widely	  advisable	  to	  design	  at	  least	  two	  Mo’s	  for	  different	  regions	  of	  the	  gene	  under	  investigation,	  for	  example	  the	  transcription	  start	  site	  (ATG	  Mo)	  and	  a	  5’	  Untranslated	  region	  (UTR	  Mo)	  (both	  are	  designed	  to	  inhibit	  translation)	  or	  a	  Mo	  targeted	  to	  an	  intron	  of	  pre	  spliced	  mRNA	  (splice	  Mo),	  preventing	  proper	  splicing,	  thus	  removing	  the	  functional	  protein.	  Splice	  Mo’s;	  however	  do	  not	  affect	  the	  maternally	  inherited	  mRNA,	  which	  is	  already	  spliced.	  A	  miss	  match	  control	  (with	  at	  least	  5	  bases	  different	  from	  functional	  Mo)	  should	  also	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be	  included	  in	  experiments	  to	  control	  for	  potential	  off	  target	  effects.	  (Eisen	  and	  Smith	  2008;	  Bill.BR	  et	  al	  2008).	  	  	  
This	  technique	  of	  gene	  knockdown	  has	  been	  demonstrated	  as	  an	  effective	  technique	  for	  use	  in	  zebrafish.	  Initial	  studies	  using	  this	  technique	  knocked	  down	  previously	  well	  characterised	  genes	  such	  as	  one-­eyed	  pinhead	  gene	  (oep),	  Shh	  and	  
nacre	  to	  determine	  the	  usefulness	  and	  reliability	  of	  Mo	  technology	  in	  zebrafish	  (Nasevicius.A	  &	  Stephen	  C.	  2000).	  Since	  the	  initial	  studies	  Mo	  injections	  have	  become	  a	  widely	  accepted	  technique	  for	  gene	  knockdown	  within	  zebrafish	  models,	  and	  have	  since	  been	  involved	  in	  many	  studies	  of	  gene	  function,	  such	  as	  identifying	  the	  role	  of	  muscle	  segment	  homebox	  genes	  msxB,	  C	  and	  E	  play	  a	  role	  in	  neural	  crest	  development	  (Pillips.	  BT	  et	  al	  2006).	  	  
Ada-­Two-­A	  Containing	  (ATAC)	  histone	  acetyltransferase	  complex	  The	  ATAC	  histone	  acetyltransferase	  (HAT)	  complex	  was	  identified	  in	  Drosophila	  in	  2008;	  since	  then	  it	  has	  been	  demonstrated	  that	  this	  HAT	  complex	  binds	  to	  both	  enhancers	  and	  promoters,	  bringing	  the	  two	  into	  proximity	  thus	  aiding	  transcription	  (Krebs.A	  Thesis	  2010;	  Nolis.IK	  et	  al	  2009).	  	  
ATAC	  has	  been	  reported	  to	  consist	  of	  several	  proteins,	  including	  the	  acetyltransferase	  GCN5	  or	  PCAF	  (only	  one	  type	  per	  complex).	  GCN5	  acetylates	  H3K9	  (Histone	  3	  Lysine	  9)	  and	  H3K14	  (histone	  modifications	  permissive	  of	  transcription)	  and	  in	  combination	  with	  adaptor	  proteins	  ADA2-­‐A	  (required	  to	  maintain	  GCN5	  association	  with	  the	  ATAC	  complex)	  and	  ADA3	  forms	  the	  catalytic	  core	  of	  ATAC	  (Orpinell.M	  et	  al	  2010).	  Other	  proteins	  associated	  with	  the	  complex	  include	  nucleosome	  remodelling	  proteins	  (E.g	  Wdr5),	  MAP	  kinase	  regulator	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(MBIP),	  the	  stress	  and	  TGFβ	  activated	  protein	  kinase	  (TAK1).	  As	  well	  as	  a	  NC2β	  histone	  fold	  protein	  that	  was	  identified	  to	  interact	  with	  TATA	  binding	  protein	  and	  inhibit	  transcription	  (Wang.	  YL	  et	  al	  2008),	  and	  zzz3	  (zinc	  finger	  protein	  ZZ	  type	  3)	  a	  potential	  DNA	  binding	  protein	  unique	  to	  ATAC,	  (Krebs.A	  Thesis	  2010)	  other	  proteins	  are	  also	  involved	  in	  this	  complex	  but	  are	  not	  mentioned	  in	  this	  report.	  This	  huge	  diversity	  of	  proteins	  involved	  in	  the	  ATAC	  complex	  highlights	  the	  intricacy	  of	  the	  potential	  functions	  with	  which	  ATAC	  may	  be	  associated.	  
ATAC	  was	  initially	  identified	  as	  structurally	  similar	  but	  functionally	  different	  to	  the	  SAGA	  	  (Spa	  ada	  Gcn5)	  complex.	  However	  closer	  analysis	  has	  determined	  that	  both	  complexes	  share	  some	  subunits	  such	  as	  GCN5	  and	  Ada3,	  while	  others	  such	  as	  zzz3	  are	  unique	  to	  ATAC	  (Krebs.A	  Thesis	  2010).	  The	  same	  group	  (Krebs.	  AR	  et	  al	  2011)	  also	  identified	  that	  SAGA	  is	  preferentially	  found	  at	  promoters,	  while	  ATAC	  was	  identified	  to	  bind	  both	  promoters	  and	  a	  distinct	  novel	  class	  of	  cell	  and	  gene	  specific	  enhancers	  that	  do	  not	  bind	  the	  common	  transcriptional	  co-­‐activators	  p300.	  	  	  
	  Studies	  into	  the	  function	  of	  ATAC	  have	  identified	  an	  association	  with	  non-­‐histone	  proteins,	  and	  cellular	  functions	  such	  as	  mitosis.	  The	  GCN5	  subunit	  in	  ATAC	  was	  shown	  to	  acetylate	  cyclin	  A	  thereby	  altering	  its	  stability,	  thus	  regulating	  downstream	  mitotic	  progression.	  While	  knockdown	  of	  ATAC	  results	  in	  delayed	  M/G1	  transition	  (Orpinell,M	  et	  al	  2010),	  	  Suganuma.T	  et	  al	  2010	  identified	  an	  alternative	  function	  of	  ATAC	  in	  Drosophila	  in	  the	  regulation	  of	  JNK	  target	  genes	  and	  p53	  when	  under	  osmoitic	  stress,	  via	  the	  MAP	  kinase	  subunit.	  They	  concluded	  that	  ATAC	  was	  vital	  for	  maintaining	  a	  balance	  between	  the	  JNK	  induced	  proliferation	  and	  p53	  mediated	  cell	  death.	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Although	  investigation	  into	  the	  role	  of	  ATAC	  and	  the	  relevant	  subunits	  is	  being	  undertaken,	  there	  is	  so	  far	  no	  investigation	  into	  the	  in	  vivo	  function	  of	  the	  zzz3	  subunit.	  
As	  mentioned,	  zzz3	  is	  a	  unique	  subunit	  of	  ATAC,	  however	  its	  function	  within	  this	  complex	  is	  as	  yet	  unknown.	  	  It	  is	  hypothesised	  that	  zzz3	  plays	  a	  role	  in	  the	  binding	  of	  ATAC	  to	  its	  specific	  enhancers	  (Krebs.A	  Thesis	  2010).	  This	  study	  therefore	  intends	  to	  investigate	  via	  reverse	  genetic	  techniques	  the	  role	  of	  zzz3	  in	  zebrafish	  development	  by	  analysing	  knock-­‐down	  phenotypes.	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Methods	  and	  Materials	  
Fish	  Care	  Initial	  investigation	  of	  zzz3	  was	  performed	  on	  wild	  type	  Danio	  rerio	  AB*,	  further	  investigation	  into	  the	  effects	  of	  zzz3	  on	  neuronal	  development	  was	  preformed	  on	  a	  stable	  transgenic	  line	  Neurogenin-­	  rfp	  (NGN-­rfp).	  All	  fish	  were	  cared	  for	  according	  to	  the	  standard	  protocols	  (Westerfield,	  M	  1995).	  Fish	  were	  maintained	  in	  mixed	  sex	  tanks	  at	  28°C,	  on	  a	  12	  hour	  light	  and	  dark	  cycle,	  and	  fed	  twice	  daily.	  
Collection	  of	  embryos	  The	  night	  before	  egg	  collection	  (post	  feeding),	  breeding	  cages	  complete	  with	  inlays	  and	  dividers	  were	  filled	  with	  water.	  Fish	  from	  desired	  tanks	  were	  paired	  up	  male	  and	  female,	  with	  no	  more	  than	  4	  fish	  per	  cage	  and	  the	  dividers	  preventing	  males	  and	  females	  interacting.	  Fish	  were	  left	  undisturbed	  over	  night.	  
The	  following	  morning,	  water	  in	  the	  breeding	  cages	  was	  replaced	  to	  aid	  cleaning	  of	  embryos,	  dividers	  were	  removed	  and	  fish	  left	  for	  approximately	  10	  minutes	  to	  breed.	  The	  cage	  inlays	  allowed	  for	  the	  eggs	  to	  fall	  to	  the	  bottom	  of	  the	  cage	  and	  protect	  them	  from	  being	  consumed	  by	  the	  adult	  fish.	  Once	  the	  eggs	  were	  laid,	  the	  inlay	  and	  the	  adult	  fish	  were	  transferred	  to	  a	  fresh	  cage	  of	  water,	  while	  the	  water	  in	  cage	  containing	  the	  embryos	  was	  poured	  through	  a	  fish	  net	  trapping	  the	  embryos	  which	  were	  in	  turn	  transferred	  to	  a	  5ml	  Petri	  dish	  with	  a	  small	  amount	  of	  fish	  water.	  This	  process	  of	  embryo	  collection	  was	  repeated	  for	  all	  fish	  pairs	  that	  had	  laid.	  Floating	  debris	  was	  carefully	  poured	  off,	  and	  the	  embryos	  were	  pipetted	  into	  separate	  5ml	  Petri	  dishes	  (one	  dish	  per	  injection	  solution)	  with	  approximately	  100	  embryos	  per	  plate.	  Embryos	  were	  swirled	  to	  reside	  in	  the	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centre	  of	  the	  dish	  before	  all	  water	  was	  removed	  using	  a	  fine	  plastic	  pipette.	  Surface	  tension	  ensures	  the	  embryos	  are	  held	  stationary	  during	  injections.	  
	  Injections	  	  Injection	  solutions	  containing	  zzz3	  Morpholinos	  (Mo)	  (Gene	  tools	  LLC)	  either	  specific	  for	  ATG	  start	  site,	  5’	  UTR,	  or	  a	  5	  base	  mismatch	  control	  (sequence	  found	  in	  Table	  1)	  were	  created	  to	  a	  concentration	  of	  100μM	  or	  200μM	  in	  a	  final	  volume	  of	  10μl.	  Included	  in	  the	  injection	  solutions	  was	  5%	  rhodamine	  dextran	  (Invitrogen)	  (required	  for	  sorting	  successfully	  injected	  embryos),	  0.5%	  phenol	  red	  (Sigma)	  (required	  to	  visualise	  the	  amount	  of	  injection	  and	  which	  embryos	  are	  injected)	  and	  nuclease-­‐	  free	  water.	  It	  should	  be	  noted	  that	  Rhodamine	  and	  Red	  Fluoresce	  
protein	  (rfp)	  both	  fluoresce	  at	  similar	  wavelengths,	  therefore	  when	  creating	  the	  injection	  solution	  for	  the	  NGN-­	  rfp	  transgenic	  embryos,	  Rhodamine	  was	  substituted	  with	  CFP-­mRNA	  at	  a	  concentration	  of	  15ng/μl.	  	  
	  	  
Morpholinos	  were	  stored	  at	  -­‐20°	  C	  to	  reduce	  the	  risk	  of	  evaporation,	  however	  this	  leaves	  the	  stock	  solutions	  prone	  to	  precipitation,	  therefore	  it	  was	  vital	  that	  before	  any	  use,	  the	  morpholinos	  were	  heated	  at	  65°C	  for	  5	  min.	  The	  homology	  of	  each	  Mo	  sequence	  was	  also	  determined	  via	  BLAST	  analysis	  against	  the	  zebrafish	  genome	  Zv9	  (UCSC).	  
Table	  1:	  	  Morpholino	  sequence	  
Morpholino	   Sequence	  Mismatched	  Control	   CATcGTGgTCTCTgCTCAcCAGgAG	  ATG	   CATGGTGCTCTCTCCTCAGCAGCAG	  5’	  UTR	   AGCTTGAACCATCCCATAGCAGTG	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Injection	  needles	  were	  created	  from	  2mm	  diameter	  capillary	  tubing	  using	  a	  heat	  filament	  needle	  puller	  to	  crate	  a	  fine	  tip.	  Needles	  were	  loaded	  with	  approximately	  2μl	  injection	  solution	  ensuring	  that	  no	  air	  bubbles	  were	  present,	  before	  being	  inserted	  in	  to	  a	  brass	  needle	  holder	  attached	  to	  a	  pressurised	  nitrogen	  cylinder.	  The	  nitrogen	  gas	  pressure	  was	  adjusted	  to	  200psi	  though	  this	  was	  often	  changed	  depending	  on	  the	  size	  of	  the	  needle	  hole	  to	  ensure	  equal	  amount	  of	  injection	  solution	  was	  dispensed	  for	  each	  morpholino.	  
Using	  a	  fine	  tipped	  forceps	  the	  top	  1/3	  of	  the	  needle	  tip	  was	  removed.	  To	  test	  that	  the	  needle	  hole	  was	  not	  too	  large	  or	  the	  air	  pressure	  too	  high	  some	  injection	  solution	  was	  ejected	  and	  the	  volume	  dispelled	  was	  visually	  assessed.	  It	  was	  important	  to	  keep	  the	  droplet	  size	  consistent	  between	  injection	  solutions	  and	  experiments.	  
Under	  a	  light	  microscope,	  the	  injection	  	  needle	  was	  gently	  inserted	  through	  the	  chorion	  and	  into	  the	  yolk/	  single	  cell	  (embryos	  that	  have	  developed	  past	  the	  single	  cell	  stage	  were	  not	  injected),	  using	  a	  foot	  pedal	  dispelled	  injection	  solution.	  If	  correctly	  administered	  the	  diameter	  of	  the	  injection	  solution	  should	  reach1/10th	  of	  the	  embryo	  diameter,	  which	  was	  determined	  by	  eye	  (Fig	  1A	  ).	  














FIG	  1:	  Injection	  of	  single	  cell	  embryos.	  A)	  Diagrammatic	  representation	  of	  
microinjection	  of	  single	  cell	  embryos.	  Injection	  solution	  (red)	  should	  occupy	  
1/10th	  of	  the	  embryo.	  B)	  Rhodamine	  sorting	  of	  injected	  embryos	  at	  20hpf.	  
Non-­‐	  injected	  embryos	  not	  visible	  under	  fluorescent	  microscope.	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Post	  injection	  care	  	  Embryos	  were	  maintained	  at	  28°C	  in	  an	  incubator,	  the	  optimal	  temperature	  for	  development.	  Following	  injection,	  embryos	  were	  re-­‐suspended	  in	  1x	  E3	  medium	  (5	  mM	  NaCl,	  0.17	  mM	  KCl	  0.33	  mM	  CaCl2,	  0.33	  mM	  MgSO4)	  with	  Gentamicin	  sulfate	  ((Fish	  Bioreagents)	  0/5ml	  in	  1litre	  1x	  E3)	  to	  prevent	  fungal	  or	  bacterial	  infection.	  After	  injections	  embryos	  were	  left	  to	  recover	  briefly	  prior	  to	  being	  cleaned.	  A	  plastic	  pipette	  was	  used	  to	  remove	  and	  discard	  all	  dead	  and	  non-­‐fertilised	  eggs.	  Living	  embryos	  were	  transferred	  to	  a	  10ml	  Petri	  dish	  and	  fresh	  E3	  Gent	  media	  was	  added.	  The	  media	  was	  changed	  every	  24	  hours	  and	  the	  dead	  removed	  to	  avoid	  paramecium	  infection.	  	  
Sorting	  Injected	  embryos	  were	  sorted	  from	  non-­‐injected	  embryos	  by	  using	  the	  fluorescent	  marker	  (rhodamine	  or	  cfp-­‐mRNA)	  incorporated	  in	  the	  injection	  solution,	  and	  viewed	  under	  a	  fluorescent	  microscope	  (Nikon).	  For	  embryos	  injected	  with	  rhodamine	  this	  was	  usually	  done	  between	  4-­‐20	  hpf	  (Fig	  1B).	  With	  CFP-­‐mRNA	  this	  sorting	  step	  could	  not	  be	  completed	  until	  CFP-­‐mRNA	  was	  translated	  into	  a	  large	  enough	  quantity	  to	  be	  visulised	  so	  was	  usually	  undertaken	  at	  around	  20hpf.	  	  
Dechorionation	  In	  order	  to	  clearly	  visualise	  phenotypes	  in	  developing	  embryos,	  it	  was	  necessary	  to	  remove	  embryos	  from	  their	  chorion.	  For	  this	  project	  embryos	  were	  dechorionated	  at	  24hpf	  enzymatically	  by	  Pronase	  type	  XIV	  (Sigma	  –	  Aldrich).	  The	  full	  protocol	  is	  found	  at	  Chen	  Lab	  protocols	  Stanford	  University.	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In	  summery,	  most	  media	  was	  removed	  from	  the	  embryos,	  	  and	  1ml	  of	  pronase	  in	  de-­‐ionised	  water	  (10mg/ml)	  was	  added	  to	  the	  embryos,	  and	  left	  for	  around	  5	  minutes.	  Occasional	  swirling	  helped	  to	  disrupt	  the	  chorion	  and	  aid	  the	  dechorionation.	  When	  approximately	  1/3	  of	  embryos	  were	  hatched,	  the	  plate	  was	  submersed	  in	  1	  liter	  of	  warmed	  fish	  water	  	  (2/3	  deionised	  water	  1/3	  Normal)	  to	  dilute	  the	  pronase.	  Water	  was	  carefully	  tipped	  off	  and	  replaced.	  This	  was	  repeated	  3	  times,	  embryos	  were	  gently	  pipette	  up	  and	  down	  3	  times	  with	  a	  plastic	  pipetted	  to	  ensure	  all	  chorions	  were	  removed,	  before	  being	  transferred	  in	  to	  a	  fresh	  10ml	  Petri	  dish	  with	  fresh	  E3	  gent	  media.	  
Imaging	  Embryos	  were	  imaged	  at	  24	  and	  48hpf,	  using	  a	  Nikon	  fluorescent	  microscope	  with	  imaging	  software	  NSI	  elements.	  	  
In	  order	  to	  obtain	  a	  clear	  lateral	  view	  of	  the	  embryos	  a	  3%	  agarose	  plate	  with	  furrows	  was	  made	  to	  hold	  embryos	  in	  the	  correct	  orientation.	  Mesab	  (0.03%	  in	  1x	  E3	  (Ethyl-­‐3-­‐aminobenzoate	  methansulfonate	  Sigma))	  was	  added	  to	  sedate	  embryos	  allowing	  easy	  manipulation	  with	  forceps	  prior	  to	  imaging.	  To	  image,	  embryos	  were	  sorted	  in	  to	  groups	  of	  similar	  phenotypes	  and	  were	  photographed	  using	  software	  NIS	  elements.	  Images	  were	  captured	  with	  bright	  field	  and	  for	  NGN-­
rfp	  transgenic	  fluorescent	  imaging.	  Identification	  of	  neurons	  in	  NGN-­rfp	  transgenic	  embryos	  was	  carried	  out	  by	  high	  magnification	  bright	  field	  and	  fluorescent	  imaging	  of	  the	  embryo	  trunk	  24hpf	  and	  48hpf.	  Neurogenin	  positive	  cells	  within	  5	  somites	  length	  above	  the	  yolk	  extension	  end	  were	  counted	  and	  documented	  for	  each	  treatment	  group.	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Results	  
Bioinformatic	  analysis	  of	  zzz3	  Mo	  As	  the	  Mo	  were	  predesigned,	  bioinformatic	  analysis	  was	  conducted	  to	  confirm	  the	  location	  and	  homology	  of	  each	  Mo	  to	  the	  zzz3	  gene	  (Chromosome	  2:	  8563505-­‐8625237:1),	  and	  to	  also	  determine	  if	  there	  was	  any	  off	  target	  homology	  that	  could	  be	  responsible	  for	  any	  phenotypes	  observed.	  The	  zzz3	  five	  base	  mismatch	  control	  Mo	  presented	  with	  0%	  homology	  to	  the	  zzz3,	  confirming	  it	  to	  be	  a	  suitable	  control.	  The	  5’	  UTR	  zzz3	  Mo	  was	  proven	  to	  be	  100%	  homologous	  to	  the	  5’	  UTR	  region	  of	  
zzz3	  at	  Ch2:	  8564791	  –	  8564814.	  While	  the	  start	  site	  Mo	  ATG	  zzz3	  showed	  a	  96%	  homology,	  with	  one	  base	  difference	  to	  zzz3	  at	  location	  Ch2:	  8564791	  –	  8564814,	  however	  this	  is	  still	  a	  high	  homology	  and	  the	  alternative	  base	  should	  not	  significantly	  effect	  the	  efficiency	  of	  the	  ATG	  Mo.	  No	  Mo	  used	  in	  this	  study	  showed	  homology	  to	  any	  other	  region	  of	  the	  zebrafish	  genome.	  
Phenotype	  analysis	  Mo	  injections	  of	  either	  zzz3	  ATG	  Mo,	  zzz3	  5’	  UTR	  Mo	  or	  zzz3	  mis-­‐matched	  control	  Mo,	  were	  injected	  in	  to	  AB*	  wild	  type	  zebra	  fish	  embryos	  at	  single	  cell	  stage.	  	  Post	  cleaning	  and	  sorting,	  embryos	  were	  incubated	  until	  viewing	  for	  phenotypes	  during	  the	  pharyngula	  stage	  of	  development	  at	  24	  hpf	  (prim	  5	  stage)	  and	  48	  hpf	  (long	  pec	  stage	  (prim	  11))	  (Kimmel.	  C.B	  et	  al	  1995).	  	  	  
A	  total	  of	  1726	  embryos	  ((100μM	  control	  n=	  274,	  ATG	  n=	  389	  and	  UTR	  n=	  275)	  (200	  μM	  control	  n=	  289,	  ATG	  n=	  247	  and	  UTR	  n=	  252))	  were	  observed	  for	  phenotypic	  abnormalities	  potentially	  caused	  by	  the	  zzz3	  Mo.	  Observed	  phenotypes	  were	  classified	  into	  four	  classes	  allowing	  the	  grouping	  of	  embryos	  with	  similar	  features	  to	  aid	  statistical	  comparison.	  Class	  1:	  (Fig	  2A	  for	  24hpf	  	  Fig	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3A	  for	  48hpf)	  embryos	  present	  with	  wild	  type	  features	  consistent	  with	  the	  observations	  reported	  by	  Kimmel.CB	  et	  al	  1995,	  during	  a	  study	  mapping	  the	  stages	  of	  zebrafish	  embryonic	  growth.	  Class	  2;	  (Fig	  2B	  for	  24hpf	  	  Fig	  3B	  for	  48hpf)	  	  embryos	  have	  mild	  phenotype	  including	  slight	  pericardial	  oedama	  and	  slightly	  reduced	  head	  and	  eye	  size.	  A	  small	  amount	  of	  cell	  death	  my	  be	  observed	  in	  the	  head	  at	  24	  hpf,	  but	  trunk	  is	  similar	  to	  wild	  type.	  Class	  3;	  (Fig	  2C	  for	  24hpf	  	  Fig	  3C	  for	  48hpf)	  embryos	  present	  with	  an	  increased	  severity	  of	  phenotype.	  	  The	  main	  feature	  visible	  was	  ventral	  tail	  (trunk)	  curvature,	  reduced	  yolk	  extension	  and	  mild	  ventralisation.	  Cell	  death	  observed	  in	  the	  head	  at	  24hpf	  leading	  to	  decreased	  head	  and	  eye	  size,	  increased	  pericardial	  oedema,	  enlarged	  heart	  (visible	  at	  48hpf)	  and	  U	  shaped	  somites	  were	  other	  features	  also	  observed.	  Class	  4;	  (Fig	  2D	  for	  24hpf	  	  Fig	  3D	  for	  48hpf)	  Most	  severe	  phenotype.	  Complete	  ventralisation,	  with	  very	  small/	  no	  head.	  Almost	  no	  yolk	  extension	  enlarged	  heart,	  pericardial	  oedema,	  sluggish	  circulation	  and	  deformed	  somites.	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Fig	  2:	  Bright	  field	  images	  of	  24hpf	  embryos	  phenotype	  injected	  with	  zzz3	  Mo.	  Y=	  
Yolk;	  YE=Yolk	  Extension;	  SH=	  Small	  head;	  PO=	  Pericardial	  oedema,;	  BT=	  Bent	  Tail;	  
BI=	  Blood	  Island;	  CD=	  cell	  death;	  Vent=	  ventralisation	  including	  blood	  island.	  A)	  
Class	  1,	  wild	  type	  embryo.	  B)	  Class	  2	  phenotype	  embryo,	  slight	  decreased	  head	  
size	  and	  pericardial	  oedema.	  C)	  Class	  3	  phenotype	  embryo,	  Bent	  tail,	  small	  head,	  
blood	  island	  and	  pericardial	  oedema.	  D)	  Class	  4	  phenotype	  embryos;	  complete	  
ventralisation	  of	  embryos,	  cell	  death	  in	  head	  visible	  and	  pericardial	  oedema.	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Fig	  3:	  Bright	  field	  images	  of	  48hpf	  embryos	  phenotype	  injected	  with	  zzz3	  Mo.	  Y=	  
Yolk;	  YE=Yolk	  Extension;	  SH=	  Small	  head;	  PO=	  Pericardial	  oedema,;	  LH=	  enlarged	  
heart	  BT=	  Bent	  Tail;	  Vent=	  ventralisation	  including	  blood	  island.	  A)	  Class	  1,	  wild	  
type	  embryo.	  B)	  Class	  2	  phenotype	  embryo,	  slight	  decreased	  head	  size	  and	  
pericardial	  oedema.	  C)	  Class	  3	  phenotype	  embryo,	  Bent	  tail,	  small	  head,	  enlarged	  
heart	  and	  pericardial	  oedema.	  D)	  Class	  4	  phenotype	  embryos;	  ventralised	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The	  more	  severe	  the	  phenotype	  the	  less	  frequently	  it	  was	  observed,	  however	  every	  phenotype	  class	  was	  reported	  for	  every	  injection	  group.	  However,	  the	  frequency	  of	  embryos	  presenting	  with	  either	  a	  class	  3	  or	  class	  4	  phenotype	  was	  greater	  in	  those	  injected	  with	  zzz3	  ATG	  Mo,	  while	  a	  class	  2	  phenotype	  was	  more	  frequently	  observed	  in	  embryos	  injected	  with	  zzz3	  UTR	  morpholino.	  
At	  24hpf,	  (Fig	  4A	  and	  B)	  the	  percentage	  of	  ATG	  injected	  embryos	  presenting	  with	  a	  class	  1	  wild	  type	  phenotype	  was	  significantly	  lower	  than	  the	  frequency	  observed	  within	  the	  control	  group.	  With	  the	  higher	  ATG	  Mo	  concentration	  presenting	  the	  most	  significant	  reduction	  in	  class	  1	  phenotype	  compared	  to	  the	  control	  group	  (100μM	  ATG	  Mo	  P=	  0.0106;	  200μM	  ATG	  Mo	  P=	  0.003).	  It	  should	  also	  be	  noted;	  that	  frequency	  of	  class	  3	  phenotype	  embryos	  at	  24hpf	  was	  significantly	  increased	  in	  200	  μM	  ATG	  Mo	  embryos	  compared	  to	  the	  control	  group	  (P=	  0.0008),	  however,	  there	  was	  also	  an	  increases	  in	  the	  frequency	  of	  control	  embryos	  presenting	  with	  either	  a	  class	  3	  or	  4	  phenotype	  when	  injected	  with	  the	  higher	  concentration	  Mo,	  suggesting	  potential	  non	  specific	  effects	  of	  the	  Mo.	  This	  trend	  was	  also	  observed	  within	  the	  100μM	  ATG	  Mo,	  however,	  though	  it	  was	  not	  statistically	  significant.	  When	  evaluating	  the	  effects	  of	  the	  UTR	  Mo,	  it	  is	  interesting	  to	  note	  that	  apart	  from	  phenotype	  class	  2	  in	  the	  200μM	  injection	  series,	  the	  prevalence	  of	  each	  phenotype	  class	  is	  very	  similar	  if	  not	  lower	  than	  the	  controls.	  
When	  directly	  comparing	  100μM	  injection	  series	  to	  the	  200μM	  injections,	  it	  was	  identified	  that	  for	  ATG	  Mo	  injections,	  the	  prevalence	  of	  class	  3	  phenotype	  was	  significantly	  more	  frequent	  in	  the	  200μm	  population	  (P=0.0006),	  while	  the	  prevalence	  of	  wild	  type	  phenotype	  (class	  1)	  was	  significantly	  more	  common	  in	  the	  100μM	  injected	  embryos	  (P=0.019).	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Most	  observations	  were	  also	  present	  at	  48hpf,	  (Fig	  5A	  and	  B)	  with	  the	  trend	  that	  ATG	  Mo	  increases	  the	  prevalence	  of	  the	  more	  severe	  phenotypes,	  in	  particular	  class	  3	  remaining	  consistent.	  However,	  due	  to	  handling	  error	  resulting	  in	  death,	  statistical	  analysis	  yielded	  less	  significant	  variation	  between	  injection	  groups	  than	  at	  24hpf.	  It	  should	  also	  be	  noted	  that	  direct	  comparison	  between	  the	  two	  concentrations	  at	  this	  time	  point	  also	  revealed	  no	  significant	  difference	  in	  phenotype	  frequency.	  
Though	  many	  embryos	  presented	  with	  a	  wild	  type	  phenotype	  after	  zzz3	  knockdown,	  it	  should	  be	  noted	  that	  a	  tend	  was	  identified,	  where	  blockage	  of	  the	  
zzz3	  transcript	  start	  site	  by	  the	  ATG	  Mo,	  resulted	  in	  an	  increased	  frequency	  of	  structural	  and	  developmental	  defects	  and	  ventralisation.	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100uM zzz3 Mo phenotype at 24hrs



















200uM zzz3 Mo Phenotype at 24hrs



























	   27	  
	  
	  
200uM zzz3 Mo Phenotype at 48hrs




















100uM zzz3 Mo Phenotype at 48 hrs
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Zzz3	  effect	  on	  neuronal	  development	  A	  preliminary	  study	  was	  conducted	  upon	  transgenic	  embryos,	  expressing	  
neurogen–rfp	  (NGN-­rfp).	  NGN	  is	  a	  transcription	  factor,	  found	  in	  many	  nerve	  cells	  within	  the	  zebrafish	  including	  the	  dorsal	  root	  ganglia,	  central	  nervous,	  neuronal	  crest	  and	  neuronal	  tube	  to	  name	  but	  a	  few,	  vital	  for	  the	  formation	  of	  peripheral	  sensory	  neurons	  (Zfin.org	  neurogenin	  1;	  McGraw	  HF	  et	  al	  2008,).	  It	  was	  therefore	  hypothesised	  that	  the	  curved	  phenotypes	  observed	  were	  due	  to	  midline	  defects	  such	  as	  loss	  of	  floor	  plate,	  which	  often	  lead	  to	  neural	  patterning	  defects.	  The	  NGN-­
rfp	  transgenic	  line	  was	  utilised	  in	  order	  to	  visualise	  the	  effect	  the	  zzz3	  Mo’s	  may	  have	  on	  neuronal	  development,	  with	  potential	  events	  such	  as	  a	  reduction	  in	  neurons,	  may	  be	  observed	  in	  embryos	  with	  the	  curved	  phenotype.	  Embryos	  were	  injected	  with	  Mo	  at	  the	  single	  cell	  stage,	  and	  then	  imaged	  at	  24(Fig	  6A-­‐D)	  and	  48hpf	  (Fig	  7A-­‐D).	  High	  magnification	  photos	  of	  the	  trunk	  at	  the	  end	  of	  the	  yolk	  extension	  were	  captured	  in	  both	  bright	  field	  and	  under	  fluorescence.	  Images	  were	  then	  overlaid	  and	  numbers	  of	  fluorescent	  neurons	  in	  the	  neuronal	  tube	  within	  5	  somites	  of	  the	  end	  of	  the	  yolk	  extension	  documented.	  As	  this	  was	  	  a	  preliminary	  study	  only	  75	  transgenic	  embryos	  were	  investigated,	  therefore	  there	  were	  not	  always	  enough	  embryos	  of	  each	  phenotypes	  to	  obtain	  a	  SEM	  value	  or	  apply	  statistical	  analysis.	  In	  order	  to	  increase	  the	  number	  of	  embryos	  recorded	  per	  phenotype,	  phenotype	  class	  1	  and	  class	  2	  were	  pooled.	  Although	  no	  conclusions	  can	  be	  drawn	  from	  the	  data	  obtained,	  there	  is	  a	  suggestion	  that	  the	  more	  severe	  phenotypes	  Class	  3	  and	  Class	  4	  present	  with	  a	  lower	  number	  of	  neurons	  in	  the	  neuronal	  tube	  (24	  hpf	  Fig	  8A-­‐B.	  48hpf	  Fig	  9A	  and	  B).	  













Fig	  6:	  Overlay	  fluorescence	  and	  bright	  field	  images	  of	  the	  trunk	  of	  NGN-­‐rfp	  
transgenic	  embryos	  at	  24hpf.	  A)	  Class	  1	  and	  2	  embryos,	  wild	  type	  or	  very	  
mild	  phenotype.	  B)	  Class	  3	  phenotype	  embryos;	  bent	  tails.	  C)	  Class	  4	  
phenotype	  embryos,	  presenting	  with	  ventralisation.	  white	  spots	  indicate	  
neurogenin	  positive	  nerves,	  white	  arrows	  indicate	  the	  5	  somite	  region	  at	  
the	  end	  of	  the	  yolk	  extention	  in	  which	  neurogenin	  nerves	  were	  counted.	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Fig	  7:	  Overlay	  fluorescence	  and	  bright	  field	  images	  of	  the	  trunk	  of	  NGN-­‐rfp	  
transgenic	  embryos	  at	  48hpf.	  A)	  Class	  1	  and	  2	  embryos,	  wild	  type	  or	  very	  mild	  
phenotype.	  B)	  Class	  3	  phenotype	  embryos;	  bent	  tails.	  C)	  Class	  4	  phenotype	  
embryos,	  presenting	  with	  ventralisation.	  White	  spots	  indicate	  neurogenin	  positive	  
nerves,	  between	  white	  arrows	  indicates	  the	  5	  somite	  region	  in	  which	  neurogenin	  






















Fig	  8:	  Frequency	  of	  neurogenin	  positive	  nerves	  in	  a	  five	  somite	  region	  
previously	  indicated	  at	  24hpf	  identifying	  a	  potential	  association	  between	  the	  
number	  of	  peripheral	  neurons	  and	  the	  severity	  of	  the	  phenotype	  	  	  
)	  100μM	  zzz3	  Mo	  injections,	  B)	  200μM	  zzz3	  Mo	  injection.	  Presented	  as	  
mean±	  SEM	  where	  possible.	  
	  










Fig	  9:	  Frequency	  of	  neurogenin	  positive	  nerves	  in	  a	  five	  somite	  region	  
previously	  indicated	  at	  24hpf	  identifying	  a	  potential	  association	  between	  the	  
number	  of	  peripheral	  neurons	  and	  the	  severity	  of	  the	  phenotype	  	  
A)	  100μM	  zzz3	  Mo	  injections,	  B)	  200μM	  zzz3	  Mo	  injection.	  Presented	  as	  
mean±	  SEM	  where	  possible	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Discussion	  This	  initial	  study	  employed	  reverse	  genetics	  to	  identify	  and	  clarify	  the	  role	  of	  the	  ATAC	  subunit	  zzz3	  upon	  zebrafish	  embryo	  phenotype.	  Knockdown	  of	  zzz3	  resulted	  in	  tail	  curvature,	  and	  general	  ventralisation	  of	  the	  embryos.	  This	  phenotype	  was	  more	  prevalent	  when	  knockdown	  was	  targeted	  to	  the	  TSS,	  with	  100μM	  ATG	  Mo	  appearing	  to	  be	  the	  most	  specific	  concentration.	  Although	  200μM	  Mo	  concentration	  also	  produced	  similar	  phenotypes,	  this	  was	  likely	  to	  be	  off	  target	  effects.	  The	  preliminary	  investigation	  conducted	  upon	  transgenic	  NGN-­rfp	  indicated	  a	  potential	  loss	  of	  neuronal	  patterning,	  which	  if	  true,	  would	  be	  consistent	  with	  the	  hypothesis	  that	  the	  curved	  phenotypes	  observed	  was	  to	  be	  due	  to	  midline	  defects	  such	  as	  loss	  of	  floor	  plate	  or	  notochord,	  although	  it	  should	  be	  noted	  that	  no	  loss	  of	  notochord	  was	  visualised	  in	  this	  investigation.	  However,	  further	  investigation	  of	  neuronal	  patterning	  is	  required	  before	  any	  conclusions	  can	  be	  drawn.	  
Interestingly	  ATAC	  has	  been	  implicated	  to	  be	  involved	  in	  nodal	  signalling	  (dorsalising	  signal	  during	  embryogenesis)	  (Krebs,	  A	  Thesis	  2010).	  Defects	  in	  this	  signaling	  pathway,	  may	  be	  responsible	  for	  the	  loss	  of	  floor	  plate	  or	  notochord	  defects,	  and	  could	  potentially	  be	  responsible	  for	  the	  curved	  and	  ventralised	  phenotype	  and	  loss	  of	  motor	  neurons	  observed	  in	  this	  study	  (Chang	  LL,	  and	  Kessler	  DS	  2010).	  However	  it	  should	  be	  noted	  there	  are	  many	  causes	  for	  a	  curved	  phenotype,	  such	  as	  the	  knock	  down	  of	  the	  transmembrane	  protein	  crim	  1	  which	  is	  involved	  in	  vascular	  development	  (Kinna,G	  et	  al	  2006),	  mutations	  within	  muscle	  
segment	  homobox	  C	  (msxC)	  (Phillips,	  B	  et	  al	  2006)	  and	  mutations	  within	  the	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hedgehog	  signaling	  pathway	  have	  also	  been	  reported	  to	  produce	  a	  similar	  bent	  phenotype	  (Brand	  et	  al	  1996).	  Brand	  et	  al	  identified	  in	  their	  study	  over	  27	  genes	  involved	  in	  the	  body	  shape	  of	  embryos,	  however	  this	  number	  is	  now	  likely	  to	  have	  increased	  as	  more	  pathways	  have	  been	  investigated.	  
Limitation	  of	  this	  study	  There	  were	  several	  limitations	  in	  this	  study,	  firstly	  maintaining	  consistent	  injection	  volume.	  As	  the	  amount	  injected	  was	  determined	  by	  eye,	  and	  the	  needle	  tips	  opened	  by	  hand,	  it	  was	  impossible	  to	  ensure	  continuous	  injection	  volume	  per	  sample.	  There	  was	  also	  variation	  between	  the	  amount	  injected	  per	  fish	  in	  the	  same	  sample;	  this	  was	  often	  due	  to	  the	  needle	  tip	  breaking,	  or	  embryos	  accidentally	  being	  double	  injected.	  A	  method	  of	  combating	  the	  inconsistency	  between	  samples	  would	  be	  to	  dispel	  one	  pump	  of	  the	  injection	  solution	  in	  to	  a	  capillary	  tube	  of	  known	  diameter	  and	  measure	  the	  length	  of	  tubing	  the	  solution	  fills.	  This	  would	  allow	  the	  volume	  dispelled	  to	  be	  calculated	  and	  therefore	  maintained	  between	  samples	  (Bill.R	  et	  al	  2009).	  	  Secondly	  due	  to	  the	  time	  constraint	  of	  manually	  imaging	  a	  large	  number	  of	  embryos	  per	  group,	  ensuring	  that	  embryos	  were	  imaged	  at	  the	  same	  developmental	  stage	  was	  not	  feasible,	  though	  by	  removing	  all	  samples	  from	  the	  incubator	  at	  the	  same	  time	  development	  was	  slowed	  during	  imaging.	  However	  this	  could	  be	  prevented	  in	  future	  investigation	  by	  the	  application	  of	  high	  throughput	  imaging	  technologies,	  such	  as	  those	  employed	  by	  Gehrig.	  J	  et	  al	  2009.	  Thirdly,	  Mo	  injections	  have	  been	  identified	  to	  have	  off	  target	  effects	  such	  as	  activation	  of	  the	  p53	  cell	  death	  pathway	  which	  is	  most	  obviously	  observed	  in	  the	  head	  (Gerety,	  S	  and	  Wilkinson	  2010;	  Eisen,	  J	  and	  Smith,	  J	  2008).	  This	  should	  be	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controlled	  for	  in	  future	  investigations.	  	  
Future	  direction	  Future	  investigation	  should	  involve	  more	  controls,	  such	  as	  including	  a	  Mo	  for	  p53	  in	  with	  the	  zzz3	  Mo	  injections,	  which	  should	  inhibit	  p53	  induced	  cell	  death	  caused	  by	  any	  off	  target	  effects	  (Gerety,	  S	  and	  Wilkinson	  2010;	  Eisen,	  J	  and	  Smith,	  J	  2008).	  Other	  investigation	  should	  focus	  on	  identifying	  if	  the	  ATG	  Mo	  and	  the	  UTR	  Mo	  are	  targeting	  the	  same	  gene.	  By	  reducing	  both	  ATG	  and	  UTR	  Mo	  concentration,	  the	  phenotypes	  reported	  in	  this	  report	  should	  only	  be	  observed	  when	  ATG	  and	  UTR	  Mo	  are	  co-­‐injected.	  It	  is	  also	  important	  to	  perform	  recovery	  experiments,	  to	  determine	  if	  the	  phenotype	  observed	  by	  knocking	  down	  zzz3	  was	  a	  true	  event.	  By	  injecting	  zzz3	  Mo	  along	  with	  zzz3	  mRNA,	  a	  wild	  type	  phenotype	  should	  be	  restored,	  thus	  proving	  the	  knock	  down	  phenotype	  was	  a	  true.	  As	  well	  as	  further	  investigation	  in	  to	  the	  effects	  of	  zzz3	  on	  NGN-­rfp	  transgenic	  embryos,	  shh	  transgenic	  fish	  (with	  shh	  associated	  to	  a	  fluorescent	  protein)	  should	  also	  be	  investigated	  as	  shh	  has	  long	  been	  used	  as	  a	  marker	  of	  the	  floor	  plate,	  due	  to	  its	  expression	  in	  normal	  floor	  plate	  development	  (Brand	  et	  al	  1996).	  This	  would	  help	  determine	  if	  zzz3	  has	  any	  effect	  on	  the	  hedgehog	  pathway	  and	  floor	  plate	  development.	  	  In	  situ	  hybridization	  should	  also	  be	  conducted	  to	  identify	  if	  zzz3	  expression	  is	  localised	  to	  a	  particular	  tissue.	  	  In	  conclusion,	  this	  study	  suggests	  but	  does	  not	  confirm	  that	  zzz3	  plays	  a	  role	  in	  midline	  development	  and	  potential	  disruption	  in	  neuronal	  patterning,	  with	  knock	  down	  of	  this	  gene	  resulting	  in	  a	  bent	  phenotype	  and	  ventralisation.	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Abstract	  	  Genomic	  imprinting	  has	  long	  been	  implicated	  as	  a	  mechanism	  of	  growth	  regulation.	  Though	  most	  genes	  are	  expressed	  by	  both	  alleles,	  around	  100	  genes	  have	  been	  classified	  as	  imprinted	  and	  therefore	  one	  allele	  is	  preferentially	  expressed	  depending	  on	  the	  epigenetic	  profile	  of	  the	  maternal	  or	  paternal	  allele,	  resulting	  in	  a	  balance	  between	  growth	  promoting	  and	  growth	  repressing	  genes.	  Defects	  in	  the	  epigenetic	  profiles	  or	  simply	  over	  expression	  of	  one	  of	  these	  imprinted	  genes,	  results	  in	  developmental	  disorders	  such	  as	  Prader-­‐Willi/Angelman	  syndrome	  (Ch15q11)	  and	  Beckwith-­‐Wiedemann	  (Ch11p15)/Silver	  Russell	  syndrome	  (SRS)	  depending	  which	  allele	  is	  affected.	  This	  study	  focused	  on	  SRS,	  a	  disorder	  associated	  with	  pre-­‐	  and	  postnatal	  growth	  retardation,	  investigating	  whether	  epimutations	  at	  six	  imprinted	  loci	  other	  than	  11p15	  had	  any	  affect	  on	  the	  disease.	  By	  utilising	  a	  novel	  methyl	  quantative	  PCR	  assay	  the	  methylation	  state	  of	  PLAGL1,	  IGF2R,	  GRB10,	  SNRPN,	  PEG3	  and	  GNAS	  was	  determined	  in	  40	  SRS	  patients	  and	  26	  non-­‐SRS	  laboratory	  controls	  and	  identified	  potential	  epimutations	  in	  30%	  of	  the	  SRS	  individuals	  at	  PLAGL1,	  IGF2R	  and	  GRB10.	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Introduction	  Epigenetic	  modifications	  are	  heritable	  modifications	  altering	  gene	  expression	  without	  any	  alteration	  to	  the	  genetic	  sequence.	  These	  modifications,	  including	  histone	  tail	  modifications	  (e.g.	  acetylation,	  methylation	  and	  phosphorylation)	  and	  DNA	  methylation,	  can	  either	  facilitate	  or	  inhibit	  transcription	  by	  altering	  the	  chromatin	  density	  and/or	  by	  regulating	  proteins	  binding	  to	  the	  DNA.	  DNA	  methylation	  is	  a	  vital	  control	  mechanism	  involved	  in	  gene	  silencing.	  By	  the	  covalent	  addition	  of	  a	  methyl	  group	  to	  cystine	  bases	  in	  CpG	  islands,	  (area	  of	  the	  genome	  rich	  in	  cystine	  (70-­‐80%)	  usually	  found	  near	  the	  promoter	  region	  of	  genes)	  transcription	  factors	  are	  unable	  to	  bind	  the	  DNA,	  thus	  preventing	  transcription.	  Methylated	  DNA	  has	  also	  been	  associated	  in	  the	  requirement	  of	  methyl	  binding	  proteins	  and	  subsequently	  histone	  deacetylases	  leading	  to	  chromatin	  remodilling	  towards	  a	  heterochromatin	  state.	  This	  mechanism	  of	  silencing	  has	  been	  implicated	  in	  X	  chromosome	  inactivation,	  cell	  differentiation,	  retroelement	  suppression	  and	  genomic	  imprinting.	  (Fritz	  EL	  et	  al	  2010;	  Lim.	  D	  and	  Maher.	  E	  2009).	  Unlike	  histone	  modifications,	  DNA	  methylation	  is	  only	  removed	  during	  primordial	  germ	  cell	  development,	  where	  all	  DNA	  methylation	  is	  cleared	  including	  parental	  imprinting.	  Imprinting	  is	  then	  restored	  during	  spermatogenesis	  or	  oogenesis	  and	  maintained	  throughout	  embryonic	  development	  (Le	  Bouc	  Y	  et	  al	  2010).	  
Genomic	  imprinting	  is	  a	  phenomenon	  of	  epigenetic	  regulation	  identified	  in	  the	  1980s	  during	  experiments	  involving	  nuclear	  transfer	  in	  mice	  embryos	  (reviewed	  by	  Lim,	  DHK,	  and	  Maher,	  E	  2010).	  Since	  then,	  around	  100	  specific	  imprinted	  genes	  have	  been	  identified	  in	  the	  human	  and	  most	  have	  been	  associated	  with	  embryonic	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development	  and	  growth.	  Most	  genes	  are	  expressed	  biallelically,	  however	  expression	  of	  imprinted	  genes	  is	  restricted	  to	  transcription	  from	  either	  the	  maternal	  or	  paternal	  allele,	  providing	  a	  balance	  between	  paternally	  expressed	  genes	  promoting	  growth	  (e.g.	  IGF2)	  and	  maternally	  expressed	  genes	  restricting	  growth	  (e.g.	  H19)	  (Butler.	  M	  2009;	  Lim,	  DHK,	  and	  Maher,	  E	  2010).	  Imprinted	  genes	  tend	  to	  be	  located	  in	  clusters	  across	  chromosomes,	  allowing	  multiple	  genes	  to	  be	  regulated	  by	  control	  elements	  known	  as	  imprinting	  centres	  (IC)	  (Lim.	  D	  and	  Maher.	  E	  2009).	  Within	  these	  regions	  of	  imprinted	  genes,	  resides	  CpG	  rich	  differentially	  methylated	  regions	  (DMR).	  These	  regions	  as	  the	  name	  describes,	  are	  differentially	  methylated	  depending	  on	  the	  parental	  origin	  of	  each	  allele,	  and	  regulate	  expression	  of	  the	  imprinted	  genes	  (for	  example	  if	  the	  maternal	  DMR	  is	  methylated	  the	  gene	  is	  repressed,	  while	  the	  paternal	  DMR	  will	  not	  methylated	  and	  therefore	  the	  gene	  is	  expressed)	  (Lim,	  DHK,	  and	  Maher,	  E.	  2010;	  Abu-­‐Amero,	  S	  et	  al	  2010).	  	  
Examples	  of	  Imprinting	  Disorders	  The	  balance	  between	  imprinted	  genes	  is	  carefully	  regulated	  to	  ensure	  proper	  growth	  and	  development.	  When	  this	  balance	  is	  disrupted,	  it	  results	  in	  overexpression	  of	  a	  once	  regulated	  gene,	  and	  can	  lead	  to	  imprinting	  disorders,	  some	  of	  which	  are	  described	  below.	  
Prader-­Willi	  Syndrome	  (PWS)	  (OMIM:	  176270)/Angelman	  Syndrome	  (AS)	  (OMIM:	  105830)	  
PWS	  and	  AS	  are	  opposite	  defects	  associated	  with	  imbalanced	  expression	  of	  imprinted	  genes	  at	  Chromosome	  15q11-­‐q13.	  	  This	  cluster	  contains	  several	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imprinted	  genes	  including,	  paternally	  expressed	  genes	  MKRN3,	  MAGEL2,	  NDN,	  
SNRPN,	  SnoRNAs	  and	  UBE3AAS	  and	  the	  maternally	  expressed	  genes	  UBE3A	  and	  
ATP10A,	  which	  is	  normally	  under	  control	  of	  an	  IC	  known	  as	  PWS-­AS	  IC,	  methylated	  on	  the	  maternal	  allele.	  	  PWS,	  was	  first	  described	  in	  1956,	  and	  is	  now	  estimated	  to	  occur	  in	  1:10,000-­‐20,000	  individuals.	  Phenotypical	  features	  initially	  present	  with	  failure	  to	  thrive,	  feeding	  difficulties,	  infantile	  hypotonia	  and	  delayed	  development	  followed	  by	  an	  insatiable	  appetite	  leading	  to	  obesity	  and	  low	  IQ	  during	  early	  childhood	  (Butler.	  M	  2009).	  There	  are	  several	  molecular	  causes	  for	  this	  disorder,	  such	  as	  deletion	  of	  the	  paternal	  imprinted	  genes	  (15%),	  maternal	  uniparental	  disomy	  (UPD)	  (25-­‐30%)	  or	  paternal	  imprinting	  defects	  (1%),	  but	  all	  result	  in	  the	  loss	  of	  the	  paternally	  expressed	  genes.	  The	  opposite	  syndrome,	  AS,	  is	  caused	  by	  loss	  of	  the	  maternally	  expressed	  genes	  within	  the	  15q11-­‐13	  cluster,	  either	  by	  deletion	  (<1%),	  Paternal	  UPD	  (7%),	  maternal	  imprinting	  defect	  (~5%)	  or	  mutation	  of	  UBE3A	  (11%).	  AS	  is	  characterised	  by	  happy	  demeanour,	  severe	  mental	  retardation	  and	  ataxic	  puppet	  like	  movements	  (Lim.	  D	  and	  Maher.	  E	  2009).	  
Imprinted	  Chromosome	  11p15.5	  Ch11p15	  contains	  two	  IC.	  IC1	  (H19	  DMR),	  located	  telomerically,	  is	  methylated	  on	  the	  paternal	  allele	  allowing	  expression	  of	  growth	  promoting	  IGF2	  and	  unmethylated	  on	  the	  maternal	  allele	  permitting	  expression	  of	  growth	  restricting	  
H19.	  	  The	  methylation	  of	  these	  loci	  on	  the	  paternal	  allele	  prevents	  the	  binding	  of	  a	  CCCTC-­‐binding	  factor	  (CTCF)	  allowing	  the	  downstream	  enhancer	  region	  to	  access	  the	  IGF2	  promoter	  region.	  In	  the	  maternal	  allele,	  CTCF	  binds	  the	  unmethylated	  DMR	  redirecting	  the	  downstream	  enhancers	  to	  the	  H19	  promoter	  (Fig	  1A).	  (Abu-­‐Amero,	  S	  et	  al	  2010;	  Bell	  AC	  and	  Felsenfeld	  G.	  et	  al	  2000)	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  IC2	  (KvDMR1	  DMR)	  located	  centromerically,	  is	  methylated	  on	  the	  maternal	  allele,	  allowing	  transcription	  of	  CDKN1C	  and	  KCNQ1	  and	  not	  methylated	  on	  the	  paternal	  allele,	  enabling	  transcription	  of	  KCNQ1OT1	  (Fig	  1A)	  (Lim,	  DHK,	  and	  Maher,	  E	  2010,	  Abu-­‐Amero,	  S	  et	  al	  2010).	  
	  



















































































Fig	  1:	  the	  11p15.5	  imprinting	  domain.	  A)	  Normal	  imprinting.	  IC1	  is	  unmethylated	  
on	  the	  maternal	  allele	  allowing	  binding	  of	  CTCF	  and	  H19	  expression.	  While	  IC2	  
unmethylated	  on	  the	  paternal	  allele	  allowing	  expression	  of	  KCNQ1OT1.	  B)	  BWS	  
IC2	  epimutation,	  methylation	  of	  maternal	  IC2	  allows	  for	  over	  expression	  of	  
paternal	  gene	  KCNQ1OT1	  and	  loss	  of	  CDKN1C.	  C)	  BWS	  IC1	  epimutations,	  gain	  of	  
maternal	  methylation	  of	  IC1	  prevents	  H19	  and	  promotes	  IGF2expression.	  D)	  BWS	  
UPD11(pat)	  disomy	  of	  paternal	  allele	  results	  in	  loss	  of	  all	  maternally	  expressed	  
genes.	  E)	  SRS	  loss	  of	  methylation	  at	  the	  paternal	  IC1	  results	  in	  over	  expression	  of	  
the	  maternal	  gene	  H19.	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Beckwith-­Wieldemann	  Syndrome	  (BWS)	  (OMIM:	  130650)	  
BWS	  is	  an	  overgrowth	  disorder	  believed	  to	  occur	  in	  1:13000.	  Although	  most	  cases	  are	  sporadic,	  an	  autosomal	  dominant	  inheritance	  has	  been	  reported	  in	  around	  10%	  -­‐15%	  of	  cases	  (Butler.	  M	  2009,	  Lim.	  D	  and	  Maher.	  E	  2009).	  The	  clinical	  phenotype	  includes	  pre-­‐	  and	  postnatal	  overgrowth,	  macroglossia,	  hypoglycaemia,	  abdominal	  wall	  defects	  such	  as	  exomphalos	  in	  the	  most	  severe	  cases,	  hemihypertrophy	  and	  a	  significantly	  increased	  risk	  of	  embryonic	  tumours	  (Lim,	  DHK,	  and	  Maher,	  2010;	  BUTLER.	  M,	  2009;	  Lim,	  D	  et	  al	  2009).	  Molecularly	  BWS	  is	  usually	  characterised	  by	  aberrant	  expression	  of	  paternally	  expressed	  IGF2	  or	  reduced	  expression	  of	  the	  maternally	  expressed	  CDKN1C	  maternally	  imprinted	  gene	  on	  chromosome	  11p15.5.	  	  The	  majority	  of	  BWS	  cases	  are	  the	  result	  of	  Loss	  of	  Methylation	  (LOM)	  at	  the	  IC2	  (KvDMR1	  DMR),	  resulting	  in	  the	  decreased	  expression	  of	  CDKN1C,	  and	  is	  responsible	  for	  approximately	  50%	  of	  BWS	  cases,	  mutations	  within	  CDKN1C	  account	  for	  5%	  of	  cases	  (Fig	  1B).	  While	  at	  IC1	  (H19	  DMR)	  Gain	  of	  Methylation	  (GOM)	  resulting	  in	  increased	  expression	  of	  the	  growth	  promoting	  gene	  IGF2	  and	  loss	  of	  H19	  accounts	  for	  2-­‐8%	  of	  cases	  (Fig	  1C).	  Paternal	  UPD	  of	  chromosome	  11	  accounts	  for	  another	  10-­‐20%	  of	  cases	  (Fig	  1D)	  although	  it	  should	  be	  noted	  that	  10-­‐20%	  of	  cases	  have	  yet	  to	  have	  a	  cause	  identified	  (Abu-­‐Amero,	  S	  et	  al	  2010;	  Lim.	  D	  and	  Maher.	  E	  2009).	  There	  is	  also	  an	  association	  between	  the	  cause	  of	  BWS	  and	  phenotype,	  with	  individuals	  presenting	  with	  either	  UPD11	  (pat)	  or	  IC1	  GOM	  having	  an	  increased	  risk	  of	  developing	  embryonic	  tumours,	  most	  commonly	  Wilms	  tumours	  	  (Butler.	  M	  2009).	  Epimutations	  within	  IC2	  have	  been	  associated	  with	  assisted	  reproductive	  technologies	  and	  increased	  prevalence	  of	  abdominal	  defects	  (Lim,	  D	  et	  al	  2009).	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Silver	  Russell	  Syndrome	  (SRS	  (OMIM	  180860))	  
SRS	  was	  first	  described	  in	  1953	  and	  is	  associated	  with	  retarded	  intrauterine	  and	  post	  natal	  growth	  (usually	  <2	  standard	  deviations	  below	  the	  national	  mean),	  although	  head	  circumference	  usually	  gives	  the	  impression	  of	  macrocephaly.	  Other	  features	  include:	  feeding	  difficulties,	  triangular	  face	  with	  prominent	  forehead,	  micrognathia,	  hemihypertrophy	  (50%	  of	  cases),	  down	  turned	  mouth,	  and	  café	  au	  lait	  patches.	  These	  features	  however	  do	  not	  impede	  life	  expectancy	  and	  become	  less	  obvious	  as	  the	  patient	  grows	  (Eggermann,	  T.	  2010;	  Bartholdi,	  D	  et	  al.	  2009).	  	  
Originally	  SRS	  was	  believed	  to	  be	  independent	  from	  BWS	  and	  associated	  with	  the	  imprinted	  gene	  cluster	  containing	  MEST	  and	  GRB10	  on	  chromosome	  7,	  due	  to	  the	  identification	  of	  UPD7(mat).	  However	  it	  has	  now	  been	  identified	  that	  SRS	  is	  the	  opposite	  of	  BWS,	  due	  to	  epimutations	  around	  11p15.5	  (Lim.	  D	  and	  Maher.	  E	  2009,	  Eggermann,	  T	  et	  al	  2008).	  UPD7	  (mat)	  has	  since	  been	  identified	  in	  only	  10%	  of	  individuals	  with	  SRS,	  while	  LOM	  at	  paternal	  IC1	  of	  11p15	  resulting	  in	  over	  expression	  of	  H19	  (Fig	  1E)	  is	  responsible	  for	  around	  40-­‐60%	  of	  cases	  and	  maternal	  disomy	  of	  11p15,	  is	  only	  estimated	  in	  1-­‐2%	  of	  cases.	  Hypomethylation	  at	  IC2	  has	  also	  been	  reported	  is	  SRS,	  however	  this	  is	  restricted	  to	  a	  few	  individual	  cases	  (Begemann,	  M	  et	  al	  2010).	  Nevertheless	  for	  >40%	  of	  SRS	  patients	  the	  cause	  is	  still	  unknown	  (Eggermann,	  T.	  2010;	  Gicquel,	  C	  et	  al	  2005).	  	  Investigations	  conducted	  by	  Bliek.	  J	  et	  al.	  2006	  have	  proposed	  that	  it	  is	  the	  LOM	  of	  H19	  that	  is	  attributed	  to	  the	  asymmetry	  observed	  in	  SRS,	  and	  also	  identified	  that	  this	  epimutation	  was	  present	  in	  some	  cases	  of	  isolated	  asymmetry	  without	  SRS.	  Other	  groups	  believe	  it	  is	  the	  occurrence	  of	  mosaicism	  that	  results	  in	  the	  asymmetry	  (Begemann,	  M	  et	  al	  2010;	  Eggermann,	  T.	  2010).	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However	  there	  are	  several	  issues	  at	  present	  that	  limit	  investigation	  of	  SRS.	  Firstly	  diagnosis	  of	  SRS;	  individuals	  with	  a	  weaker	  phenotype	  are	  often	  missed,	  and	  diagnosis	  is	  largely	  dependent	  on	  the	  experience	  of	  the	  clinician.	  Several	  scoring	  systems	  have	  now	  been	  developed	  to	  aid	  diagnosis	  (Bartholdi,	  D	  et	  al.	  2008,1).	  
Secondly	  the	  presence	  of	  mosaicism	  in	  SRS,	  where	  it	  has	  been	  reported	  that	  methylation	  state	  differs	  in	  different	  tissues	  within	  the	  same	  individual	  (Begemann,	  M	  et	  al	  2010;	  Eggermann,	  T.	  2010),	  thus	  increasing	  the	  risk	  of	  missing	  vital	  molecular	  features	  during	  diagnosis	  and	  further	  investigation.	  
Imprinting	  disorders	  and	  assisted	  reproductive	  technologies	  (ART)	  ART	  has	  become	  a	  more	  common	  method	  of	  conception	  since	  its	  creation,	  with	  it	  now	  accounting	  for	  1-­‐3%	  of	  worldwide	  births	  since	  2002.	  However	  ART	  has	  now	  been	  associated	  with	  an	  increase	  in	  imprinting	  disorders,	  particularly	  BWS	  and	  AS	  as	  these	  are	  the	  most	  intensely	  studied.	  There	  is	  currently	  insufficient	  evidence	  linking	  ART	  to	  SRS	  (Owen,	  CM	  and	  Segars,	  JH.	  2009,	  Lim.	  D	  and	  Maher.	  E	  2009).	  Lim,	  D	  et	  al	  2009	  identified	  that	  4%	  of	  BWS	  cases	  had	  a	  history	  of	  ART	  compared	  to	  1.2%	  in	  the	  general	  population	  and	  that	  these	  individuals	  had	  an	  increased	  chance	  of	  presenting	  with	  LOM	  at	  IC2.	  They	  also	  concluded	  a	  phenotypical	  difference	  between	  BWS	  patients	  conceived	  by	  ART	  compared	  to	  those	  that	  conceived	  naturally;	  for	  example	  ART	  conceived	  BWS	  patients	  had	  a	  lower	  risk	  of	  exomphalos	  but	  increased	  risk	  of	  non-­‐Wilms	  tumors,	  as	  well	  as	  reporting	  that	  ART	  conceived	  BWS	  individuals	  were	  more	  likely	  to	  present	  with	  LOM	  at	  DMRs	  outside	  of	  the	  11p15.5	  region.	  Although	  the	  absolute	  risk	  of	  imprinting	  defects	  in	  ART	  cases	  is	  reported	  to	  be	  <1%	  (Bowdin	  S.	  et	  al	  2007),	  the	  mechanism	  behind	  this	  observation	  with	  ART	  is	  still	  unclear.	  It	  is	  hypothesised	  that	  either	  the	  technique	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involved	  with	  ART	  or	  the	  infertility	  itself	  is	  a	  factor	  due	  to	  the	  epigenetic	  disruption	  (Lim.	  D	  and	  Maher.	  E	  2009).	  
Aims	  and	  Hypothesised	  genes	  linked	  to	  SRS	  The	  aim	  of	  this	  study	  was	  to	  investigate	  the	  epigenetic	  profile	  of	  SRS	  patients	  at	  a	  selection	  of	  imprinted	  loci,	  and	  to	  determine	  if	  there	  is	  any	  variation	  in	  methylation	  or	  phenotype	  between	  SRS	  individuals	  with	  LOM	  at	  H19	  and	  those	  with	  normal	  methylation.	  Both	  studies	  on	  BWS	  patients	  and	  patients	  with	  TNDM,	  have	  shown	  LOM	  at	  other	  loci	  (Eggermann,	  T.	  2010;	  Bliek,	  J.	  et	  al	  2009),	  therefore	  it	  is	  feasible	  that	  the	  same	  may	  occur	  in	  SRS.	  The	  following	  loci	  were	  investigated	  based	  on	  their	  known	  role	  in	  other	  imprinted	  defects:	  
PLAGL1	  (Pleiomorphic	  adenoma	  gene-­like	  1	  (OMIM	  603044))	  6q24-­‐q25:	  Over	  expression	  of	  PLAGL1	  has	  been	  implicated	  in	  the	  imprinting	  disorder	  Transient	  Neonatal	  Diabetes	  Mellitus	  (TNDM)(Lim.	  D	  and	  Maher.	  E	  2009).	  A	  study	  by	  Bliek,	  J.	  et	  al	  2009	  demonstrated	  the	  LOM	  at	  both	  PLAGL1	  and	  GNAS	  in	  BWS	  patients,	  suggesting	  that	  these	  loci	  might	  also	  be	  affected	  in	  SRS.	  
GNAS	  (GNAS	  Complex	  Locus,	  OMIM:	  139320)	  Ch	  20q13.3:	  GNAS	  has	  been	  implicated	  in	  pseudohypoparathyroidism	  (Albright	  hereditary	  osteodystophy)	  and	  is	  a	  widely	  investigated	  imprinted	  gene.	  (Butler.	  M	  2009;	  Lim.	  D	  and	  Maher.	  E	  2009)	  
IGF2R	  (Insulin	  Like	  Growth	  Factor	  II	  Receptor	  OMIM:	  147280)	  Ch	  6q26:	  The	  receptor	  for	  the	  growth	  promoting	  IGF2,	  reducing	  circulating	  IGF2	  levels	  and	  regulating	  the	  proliferative	  effect.	  IGF2R	  is	  expressed	  on	  only	  one	  allele	  however	  it	  is	  imprinted	  in	  a	  complex	  manor	  (OMIM).	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GRB10	  (Growth	  Factor	  Receptor	  Bound	  Protein	  OMIM:	  601523),	  Ch7p12.2:	  GRB10	  was	  identified	  as	  a	  candidate	  gene	  in	  the	  region	  prone	  to	  translocation	  in	  UPD7	  (mat)	  cases.	  A	  mutation	  in	  this	  gene	  was	  also	  reported	  in	  a	  SRS	  case	  study	  (Yoshihashi,	  H	  et	  al	  2000.).	  GRB10	  encodes	  an	  adaptor	  protein	  that	  interacts	  with	  tyrosine	  kinase	  receptors,	  and	  is	  believed	  to	  negatively	  regulate	  the	  effects	  of	  insulin	  signaling	  with	  loss	  of	  GRB10	  resulting	  in	  fetal	  overgrowth	  (Charalambous	  M,	  et	  al	  2003;	  Abu-­‐Amero,	  S	  et	  al	  2010).	  	  
SNRPN	  (Small	  Nuclear	  Ribnucleoprotein	  Polypeptide	  N,	  OMIM:	  182279)	  Ch15q11.2:	  
SNRPN	  is	  a	  maternally	  imprinted	  gene	  involved	  in	  RNA	  processing,	  with	  a	  long	  tail	  containing	  small	  nucleolar	  RNAs	  	  that	  are	  alternatively	  spliced	  post	  transcription;	  	  and	  regulate	  expression	  of	  maternally	  expressed	  imprinted	  genes	  on	  the	  15q11-­‐13	  cluster.	  Disruption	  of	  this	  gene	  is	  associated	  with	  PWS	  (Lim.	  D	  and	  Maher.	  E	  2009;	  Lim,	  DHK,	  and	  Maher,	  E	  2010),	  while	  delinearisation	  and	  disruption	  of	  Ch15	  has	  been	  reported	  in	  several	  case	  studies	  of	  SRS	  (Tamura	  T,	  et	  al	  1993;	  Wilson	  GN,	  et	  al	  1985).	  
PEG3	  (Paternally	  Expressed	  Gene	  3	  3OMIM:	  601483;)	  CH19q13.4:	  In	  vivo	  studies	  demonstrate	  that	  disruption	  of	  this	  paternal	  gene	  results	  in	  smaller	  offspring.	  It	  was	  also	  investigated	  in	  a	  study	  on	  atypical	  PWS	  subjects	  (Bale,	  E	  et	  al	  2011)	  and	  therefore	  was	  included	  in	  this	  study.	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Method	  and	  Materials	  
Patients	  DNA	  samples	  were	  obtained	  from	  individuals	  with	  suspected	  SRS	  for	  diagnosis,	  and	  stored	  at	  -­‐80°C	  until	  required	  for	  further	  methylation	  studies.	  Informed	  consent	  had	  been	  obtained	  from	  all	  individuals/families.	  
In	  this	  study	  initial	  investigation	  was	  performed	  on	  a	  cohort	  of	  66	  samples	  (26	  non	  SRS	  laboratory	  controls	  and	  40	  patients	  referred	  for	  a	  possible	  diagnosis	  of	  SRS).	  All	  of	  the	  patient	  groups	  had	  no	  evidence	  of	  UPD7	  and	  a	  normal	  karyotype.	  Prior	  to	  the	  study	  commencing,	  18	  of	  the	  SRS	  group	  were	  identified	  during	  diagnosis	  to	  have	  LOM	  at	  H19	  DMR	  (11p15.5)	  and	  the	  other	  22	  had	  normal	  H19	  DMR	  methylation.	  	  
Upon	  retrieval,	  genomic	  DNA	  samples	  were	  vortexed	  and	  centrifuged.	  Samples	  were	  then	  diluted	  1:10	  in	  distilled	  nuclease	  free	  water	  (dH20)	  in	  separate	  eppendorf	  tubes	  to	  a	  total	  volume	  of	  20μl	  ready	  for	  quantification	  by	  Nanodrop	  spectrophotometer	  ND-­‐1000.	  	  Nanodrop	  quantification	  was	  employed	  not	  only	  to	  determine	  genomic	  DNA	  concentration,	  but	  also	  to	  evaluate	  purity	  by	  observing	  the	  260/280	  and	  260/230	  ratios,	  both	  of	  which	  should	  be	  greater	  than	  1.80.	  If	  either	  ratio	  were	  lower	  than	  the	  stated	  threshold	  it	  would	  indicate	  the	  presence	  of	  protein,	  phenol	  or	  other	  contaminants	  and	  could	  degrade	  the	  genomic	  DNA	  or	  affect	  the	  activity	  of	  the	  restriction	  enzymes	  used	  in	  the	  methylation	  studies.	  Poor	  quality	  DNA	  was	  excluded	  from	  this	  study.	  (Thermo	  scientific	  NanoDrop	  1000	  Spectrophotometer	  manual	  http://www.nanodrop.com/Library/nd-­1000-­v3.7-­
users-­manual-­8.5x11.pdf)	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Methylation	  Studies	  All	  methylation	  analysis	  was	  performed	  using	  the	  EpiTect	  Methyl	  qPCR	  Assay	  (SAbiosciences	  Qiagen)	  following	  the	  protocols	  provided	  and	  summarised	  below.	  	  The	  Assay	  works	  on	  the	  principle	  of	  digesting	  genomic	  DNA	  with	  either	  methylation	  sensitive	  or	  methylation	  dependent	  enzymes	  followed	  by	  quantification	  of	  the	  remaining	  undigested	  DNA	  by	  real	  time	  PCR	  (qPCR)	  providing	  an	  indication	  to	  the	  methylation	  state	  of	  the	  CpG	  region	  investigated.	  The	  benefit	  of	  this	  assay	  over	  other	  techniques	  traditionally	  employed	  to	  detect	  DNA	  methylation,	  such	  as	  bisulfite	  sequencing	  and	  methylation	  specific	  PCR,	  is	  the	  reduced	  time	  constraints,	  simple	  technique	  with	  a	  semi	  high	  throughput,	  reliablility,	  and	  all	  samples	  are	  internally	  controlled	  excluding	  the	  need	  to	  run	  controls	  in	  the	  PCR	  such	  as	  house	  keeping	  genes.	  As	  each	  assay	  is	  predesigned,	  there	  is	  also	  no	  need	  for	  PCR	  primer	  design	  or	  optimisation.	  	  
Digests	  Firstly	  DNA	  methylation	  digest	  was	  conducted	  using	  a	  Methyl-­‐Profiler	  Enzyme	  kit	  (MeA-­‐03	  SAbiosciences	  Qiagen).	  In	  summary	  a	  master	  mix	  of	  input	  DNA	  was	  created	  consisting	  of	  26μl	  5X	  Digestion	  Buffer,	  0.5μg	  Genomic	  DNA	  and	  dH2O	  added	  to	  a	  final	  volume	  of	  120μl,	  before	  mixing	  by	  vortex.	  	  Four	  digests	  were	  set	  up	  per	  master	  mix	  solution	  in	  a	  96	  well	  plate	  (12	  patients	  per	  plate)	  
1) Mock	  digest	  (Mo):	  dH2O	  was	  added	  instead	  of	  restriction	  enzymes,	  to	  the	  genomic	  DNA,	  therefore	  representing	  the	  total	  volume	  of	  input	  ingredients	  and	  acts	  as	  the	  input	  control	  for	  the	  qPCR	  2) Methylation	  Sensitive	  Digest	  (Ms):	  Genomic	  DNA	  master	  mix	  was	  added	  to	  a	  methylation	  sensitive	  enzyme	  that	  only	  digests	  unmethylated	  and	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partially	  methylated	  DNA.	  This	  ment	  that	  during	  qPCR	  hypermethylated	  DNA	  would	  be	  amplified	  and	  quantified.	  3) Methylation	  Dependent	  Digest	  (Md):	  Genomic	  DNA	  master	  mix	  was	  added	  to	  a	  methylation	  dependent	  enzyme	  that	  preferentially	  digests	  methylated	  DNA.	  This	  ment	  that	  during	  qPCR	  unmethylated	  DNA	  would	  be	  amplified	  and	  quantified.	  4) Double	  Digest	  (Msd):	  Both	  methylation	  sensitive	  and	  methylation	  dependent	  enzymes	  were	  incubated	  with	  the	  genomic	  DNA	  master	  mix,	  digesting	  the	  entire	  DNA.	  This	  control	  was	  included	  to	  quantify	  the	  background	  noise	  during	  the	  qPCR.	  
It	  was	  important	  that	  for	  each	  digest	  the	  same	  amount	  of	  genomic	  DNA	  was	  added	  to	  avoid	  a	  biassed	  or	  inaccurate	  result	  during	  the	  PCR.	  	  Samples	  were	  sealed	  then	  incubated	  on	  tetrad	  PCR	  machine	  at	  37°C	  for	  16	  hours,	  followed	  by	  20	  minutes	  at	  65°C	  to	  denature	  and	  inactivate	  the	  digestion	  enzymes.	  The	  stock	  DNA	  digests	  were	  then	  stored	  at	  -­‐20°C	  until	  required	  for	  PCR,	  when	  defrosted	  samples	  were	  briefly	  centrifuged,	  before	  required	  volumes	  of	  samples	  were	  aliquoted	  out	  onto	  to	  PCR	  plate.	  To	  ensure	  digestion	  was	  complete	  the	  assay	  was	  designed	  so	  that	  each	  sample	  was	  incubated	  for	  longer	  than	  needed	  and	  had	  an	  excess	  of	  restriction	  enzyme.	  
PCR	  To	  determine	  the	  methylation	  status	  of	  specific	  loci,	  qPCR	  was	  performed	  using	  predesigned	  and	  pre-­‐optimised	  methyl-­‐profiler	  DNA	  methylation	  qPCR	  primers.	  PCR	  master	  mix	  was	  created	  following	  the	  instructions	  in	  the	  manual.	  Each	  well	  was	  analysed	  by	  PCR	  consisting	  of	  RT2	  SYBR	  Green	  PCR	  Sensi	  mix	  (includes	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Hotstart	  DNA	  polymerase),	  dH2O,	  restriction	  enzyme	  digest	  (Mo,	  Ms,	  Md,	  Msd)	  and	  optimised	  methyl-­‐profiler	  DNA	  methylation	  qPCR	  primer	  set,	  for	  the	  specific	  CpG	  island	  of	  investigated	  loci.	  Following	  vortexing	  and	  a	  brief	  spin	  down	  PCR	  was	  run	  on	  Bio-­‐Rad	  I	  cycler	  IQ5	  qPCR	  machine	  with	  the	  following	  program	  (Table	  1)	  
	  
Table	  1:	  q-­‐PCR	  cycle	  program	  
Cycles	  	   Temperature	   Time	  1	   95°C	   10	  minutes	  99°C	   30	  seconds	  3	   72°C	   1	  minute	  97°C	   15	  seconds	  40	   72°C	   1	  minute	  Melt	  Curve	  	   Set	  according	  to	  machine	  
	  
The	  Initial	  10	  minute	  cycle	  1	  was	  required	  to	  activate	  the	  Hot	  Start	  DNA	  polymerase	  to	  allow	  successful	  amplification	  of	  DNA.	  The	  melt	  curve	  analysis	  was	  included	  as	  a	  control	  to	  ensure	  complete	  PCR	  amplification.	  After	  completion	  of	  the	  PCR,	  Ct	  values	  were	  collected	  for	  analysis	  of	  methylation	  state.	  The	  assay	  provided	  a	  predefined	  analysis	  spreadsheet	  that	  determined	  the	  percent	  of	  DNA	  that	  was	  hypermethylated	  (HM,	  >60%	  methylated),	  unmethylated	  (UM,	  0%	  methylated)	  and	  intermediately	  methylated	  (IM,	  between	  0	  and	  60%	  methylated)	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in	  relation	  the	  Ct	  value	  of	  the	  mock	  digest	  minus	  the	  double	  digest	  (Background	  noise).	  	  The	  statistical	  analysis	  employed	  also	  calculated	  the	  efficiency	  of	  the	  enzyme	  digest	  setting	  the	  threshold	  for	  successful	  digests	  at	  75%	  of	  DNA	  digested	  (EpiTect	  Methyl	  qPCR	  assay	  Manuel	  http://www.sabiosciences.com/support_manual.php?pfamily=dnamethylation).	  
This	  methylation	  study	  looked	  at	  the	  HM	  levels	  of	  up	  to	  40	  SRS	  (proven	  or	  suspected)	  patients	  compared	  to	  controls	  (n=26)	  at	  various	  imprinted	  loci	  that	  might,	  based	  on	  previous	  literature,	  represent	  potential	  areas	  of	  altered	  methylation	  in	  SRS.	  Loci	  investigated	  and	  primer	  locations	  are	  listed	  in	  Table	  2.	  
Table	  2:	  qPCR	  primer	  location	  and	  target	  gene.	  Sequence	  was	  not	  disclosed.	  











PLAGL1	  	   Ch6q24-­‐q25	  	  	   Ch6:	  144370609-­‐	  144371540	   Ch6:	  144371270	   TNDM	  
IGF2R	  	   Ch6q26	  	  	   Ch6:	  160426265-­‐	  160427502	   Ch6:	  160427151	   Potentially	  involved	  in	  SRS	  
GRB10	  	   Ch7p12.2	  	  	  	  	   Ch7:	  50849753-­‐	  50850871	   Ch7:	  50850409	   Potentially	  involved	  in	  SRS	  
PEG3	   CH19q13.4	   CH19:	  62043812-­‐	  62044146	   CH19:	  62044146	   -­‐	  
SNRPN	   Ch15q11.2	   Ch15:	  22751128-­‐	  22752147	   Ch15:	  22751228	   PWS	  
GNAS	   Ch	  20q13.3	   Ch20:	  56861703-­‐56861911	  	   Ch20:	  56861806	   Albright	  hereditary	  osteodystophy	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Data	  Analysis	  LOM	  or	  GOM	  was	  classified	  as	  any	  HM	  value	  either	  2	  standard	  deviations	  (SD)	  below	  or	  above	  the	  mean	  of	  all	  SRS	  patients	  and	  controls	  respectively.	  Ensuring	  at	  least	  a	  95%	  confidence	  for	  controls.	  All	  samples	  that	  showed	  apparent	  LOM	  or	  GOM	  at	  any	  loci	  or	  individuals	  with	  an	  IM	  value	  greater	  than	  5.5%	  were	  repeated,	  to	  ensure	  the	  result	  was	  true.	  
All	  data	  analysis	  was	  conducted	  using	  Excel2008	  and	  GraphPad	  Prism	  software.	  Methylation	  data	  is	  presented	  with	  mean	  ±	  SEM	  displayed.	  Statistical	  tests	  conducted	  included	  Students	  t-­‐test	  and	  Chi-­‐squared,	  Fisher’s	  Exact	  Tests	  and	  Pearsons	  correlation	  co-­‐efficitent.	  
	  
	   55	  
Results	  
Comparison	  of	  clinical	  features	  	  The	  first	  step	  in	  this	  study	  was	  to	  determine	  if	  there	  was	  any	  correlation	  between	  the	  presented	  clinical	  features	  and	  the	  known	  molecular	  information	  obtained	  during	  diagnosis.	  All	  individuals	  included	  in	  this	  study	  presented	  with	  short	  stature	  and	  had	  been	  suspected	  of	  having	  SRS.	  During	  diagnosis	  genetic	  abnormalities	  and	  UPD7	  had	  been	  excluded	  in	  all	  cases.	  The	  available	  clinical	  data	  for	  each	  of	  the	  case	  subjects	  is	  presented	  in	  Appendix	  1.	  	  
The	  clinical	  features	  of	  patients	  with	  and	  without	  LOM	  at	  H19	  were	  compared	  (see	  Table	  1).	  Features	  such	  as	  hemihypertrophy,	  prominent	  forehead,	  down	  turned	  mouth,	  fifth	  figure	  clinodactyly	  and	  micrognathia	  appeared	  to	  be	  more	  frequently	  observed	  in	  SRS	  individuals	  with	  H19	  LOM	  than	  those	  without	  this	  LOM	  (see	  Table	  1	  and	  Figure	  1).	  This	  suggests	  that	  individuals	  with	  H19	  LOM	  are	  more	  likely	  to	  present	  with	  clinical	  features	  of	  SRS	  and	  possibly	  a	  more	  severe	  phenotype	  than	  with	  normal	  H19	  methylation	  (Table	  3	  and	  Fig	  2).	  
It	  should	  be	  noted	  that	  for	  phenotypical	  analysis	  case	  SRS	  18	  was	  excluded,	  as	  initially	  the	  patient	  was	  suspected	  of	  having	  BWS,	  however	  atypical	  BWS	  features,	  including	  unsteady	  gait,	  provoked	  further	  investigation	  and	  uncovered	  evidence	  of	  
H19	  LOM	  during	  molecular	  genetic	  analysis.	  This	  was	  contradictory	  to	  the	  expected	  result	  for	  BWS	  where	  hypermethylation	  of	  the	  11p15.5	  loci	  is	  usually	  observed,	  and	  suggests	  a	  molecular	  diagnosis	  of	  SRS,	  allowing	  this	  individual	  to	  be	  included	  in	  the	  subsequent	  methylation	  studies.	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There	  was	  no	  difference	  in	  the	  frequency	  of	  children	  conceived	  by	  ART	  in	  the	  two	  SRS	  groups	  (two	  in	  each	  group),	  however,	  the	  overall	  frequency	  of	  ART	  births	  within	  the	  SRS	  population	  (10.2%,	  (4/39)	  if	  SRS18	  is	  excluded	  and	  12.5%	  (5/40)	  if	  SRS18	  is	  included)	  was	  higher	  than	  expected,	  as	  the	  expected	  frequency	  of	  an	  imprinting	  condition	  in	  ART	  births	  in	  the	  UK	  population	  is	  approximately	  1%	  (Lim	  et	  al	  2009).	  
It	  has	  previously	  been	  reported	  that	  the	  frequency	  of	  ART	  births	  is	  increased	  in	  BWS	  children	  (in	  particular	  those	  with	  LOM	  at	  KvDMR1),	  that	  there	  are	  phenotypic	  differences	  between	  ART-­‐conceived	  and	  naturally	  conceived	  BWS	  children	  and	  that	  ART-­‐conceived	  BWS	  children	  are	  more	  likely	  to	  have	  hypomethylation	  outside	  11p15.5	  (Lim	  et	  al	  2009).	  These	  observations	  raised	  several	  questions.	  Firstly,	  do	  SRS	  patients	  also	  show	  evidence	  of	  hypomethylation	  at	  other	  imprinted	  loci	  outside	  11p15.5?	  Secondly,	  if	  hypomethylation	  is	  observed,	  are	  there	  differences	  in	  frequency	  between	  those	  with	  and	  without	  H19	  LOM	  and	  does	  this	  influence	  phenotype?	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Table	  3:	  Summary	  of	  the	  clinical	  data	  of	  all	  Silver	  Russell	  patients	  tested	  	  Silver	  Russell	  Clinical	  data	  	   	   All	   H19	  Normal	   H19	  LOM	   P	  Value	  	   Number	  of	  cases	   39	   22	   17	   -­‐	  	   	   	   	   	   	  Sex	   Male	   13/39	   7/22	   6/17	   -­‐	  	   Female	   20/39	   12/22	   8/17	   -­‐	  	   Unknown	   6/39	   3/22	   3/17	   -­‐	  	   	   	   	   	   	  	   Normal	  karyotype	   39/39	   22/22	   17/17	   -­‐	  	   UPD7	   0/39	   0/22	   0/17	   -­‐	  	   H19	  LOM	   17/39	   0/22	   17/17	   -­‐	  	   	   	   	   	  ART	  conception	   4/39	   2/22	   2/17	   -­‐	  	   	   	   	   	  Pregnancy	   	   	   	   	  	   Preterm	  (<37	  weeks)	   11/39	   6/22	   5/17	   -­‐	  	   Term	  (37-­‐41	  weeks)	   28/39	   16/22	   12/17	   -­‐	  	   	   	   	   	  Prenatal	  period	  (<1	  month)	   	   	   	   	  	   Intensive	  care	   18/39	   7/22	   11/17	   0.056	  	   Feeding	  difficulties	   20/39	   11/22	   9/17	   1.000	  	   Hypoglycaemia	   6/39	   2/22	   4/17	   0.374	  	   	   	   	   	  Postnatal	  period	  (>1	  month)	   	   	   	   	  	   Feeding	  difficulties	   23/39	   14/22	   9/17	   0.531	  	   nasogastric	  tube	   7/39	   5/22	   2/17	   0.438	  	   Gastromy	  fed	   2/39	   1/22	   1/17	   1.0000	  	   Hypoglycaemia	   3/39	   0/22	   3/17	   0.074	  	   Café	  au	  lait	  patches	   6/39	   4/22	   2/17	   0.679	  	   Visual	  defects	   3/39	   2/22	   1/17	   0.374	  	   Mental	  retardation	   11/39	   7/22	   4/17	   0.725	  	   	   	   	   	  Other	  features	   	   	   	   	  	   Hemihypertrophy	   17/39	   6/22	   11/17	   0.026	  	   Delayed	  bone	  age	   7/39	   5/22	   2/17	   0.438	  	   Facial	  asymmetry	   9/39	   4/22	   5/17	   0.465	  	   Prominent	  forehead	   27/39	   11/22	   16/17	   0.005	  	   Down	  turned	  mouth	   17/39	   5/22	   12/17	   0.004	  	   Dental	  crowding	   1/39	   0/22	   1/17	   0.436	  	   Micrognathia	   8/39	   3/22	   5/17	   0.261	  	   Fifth	  finger	  clinodactyly	   24/39	   10/22	   14/17	   0.024	  	   Congenital	  cardiac	  malformations	   6/39	   4/22	   2/17	   0.679	  	   Camptodactyly	   2/39	   0/22	   2/17	   0.183	  Clinical	  features	  numerically	  summarised,	  comparing	  Patients	  with	  H19	  LOM	  SRS	  and	  H19	  normal	  SRS	  individuals.	  Statistical	  difference	  between	  the	  two	  SRS	  groups	  was	  determined	  by	  Fisher	  extract	  tests.	  	  P	  values	  in	  bold	  are	  significant	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Methylation	  state	  at	  imprinted	  loci	  in	  SRS	  patients	  Investigation	  of	  the	  methylation	  at	  imprinted	  loci	  other	  than	  H19	  was	  conducted	  using	  EpiTect	  Methyl	  qPCR	  Assay	  on	  DNA	  from	  26	  non-­‐SRS	  controls	  and	  40	  SRS	  cases	  previously	  described.	  	  	  
The	  methylation	  state	  of	  the	  following	  imprinted	  genes	  was	  determined	  and	  comparison	  was	  made	  for	  the	  results	  between	  (a)	  controls	  and	  (b)	  the	  SRS	  group	  (Fig	  3	  A-­‐E).	  	  	  
Mean	  HM	  percentage	  at	  PLAGL1,	  IGF2R,	  GRB10,	  SNRPN	  and	  PEG3	  was	  not	  significantly	  different	  between	  control	  and	  SRS.	  Further	  inspection	  of	  the	  distribution	  of	  methylation	  between	  the	  control	  and	  SRS	  groups	  revealed	  evidence	  of	  outliers	  at	  some	  loci	  thus	  indicating	  potential	  methylation	  variation	  between	  SRS	  patients	  and	  the	  normal	  population.	  
Interestingly	  PEG3	  showed	  high	  variability	  in	  methylation	  within	  the	  control	  group	  and	  displayed	  potential	  clustering	  of	  sub	  populations.	  The	  high	  variability	  within	  the	  control	  population	  prevents	  any	  conclusion	  being	  drawn	  about	  the	  methylation	  status	  of	  this	  gene	  in	  SRS.	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Imprinted	  loci	  methylation	  state	  in	  H19	  LOM	  and	  H19	  normal	  SRS	  cases	  To	  establish	  if	  the	  SRS	  methylation	  outliers	  reported	  in	  Fig	  3	  are	  significant	  and	  localised	  to	  either	  the	  H19	  LOM	  SRS	  or	  the	  H19	  normal	  SRS	  population,	  the	  data	  was	  re-­‐analysed,	  separating	  the	  two	  sub	  populations	  (Fig	  4).	  Further	  analysis	  showed	  that	  all	  outlier	  values	  were	  found	  in	  SRS	  patients	  with	  H19	  LOM.	  	  
Mean	  HM	  percentage	  at	  IGF2R	  (P=0.04)	  and	  GRB10	  (P=	  0.003),	  in	  H19	  LOM	  SRS	  population	  was	  significantly	  lower	  than	  control	  population.	  	  
	  Most	  H19	  LOM	  individuals	  however	  have	  a	  HM	  value	  for	  IGF2R	  on	  trend	  with	  norm.	  The	  reduced	  average	  could	  therefore	  be	  attributed	  to	  three	  outliers	  that	  showed	  large	  amount	  of	  LOM	  (Fig	  4B)	  indicating	  that	  most	  cases	  of	  H19	  LOM	  SRS	  are	  not	  associated	  with	  epimutation	  at	  IGF2R	  loci.	  	  
GRB10	  however	  (Fig	  4C)	  presented	  the	  most	  interesting	  pattern	  of	  methylation.	  Potential	  clustering	  into	  4	  groups	  was	  observed	  within	  this	  population,	  with	  one	  cluster	  showing	  almost	  complete	  LOM.	  This	  pattern	  of	  clustering	  was	  not	  observed	  in	  the	  H19	  normal	  SRS	  population	  and	  two	  clusters	  were	  seen	  within	  the	  control	  population.	  The	  implications	  of	  this	  observation	  have	  yet	  to	  be	  determined	  and	  a	  larger	  cohort	  of	  individuals	  should	  be	  examined	  to	  determine	  if	  this	  is	  a	  true	  observation.	  
A	  preliminary	  study	  of	  GNAS	  was	  also	  conducted	  on	  H19	  LOM	  SRS	  and	  14	  controls,	  however	  technical	  issues	  prevented	  investigation	  of	  this	  locus	  on	  H19	  normal	  SRS,	  so	  no	  conclusions	  as	  to	  methylation	  state	  can	  be	  drawn	  (Fig	  4F).	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Nevertheless	  it	  does	  appear	  that	  within	  the	  H19	  LOM	  SRS	  population	  there	  are	  2	  outliers	  with	  increased	  methylation,	  though	  further	  investigation	  is	  required.	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Correlation	  between	  methylation	  states	  of	  imprinted	  loci	  Investigation	  was	  conducted	  to	  identify	  any	  correlation	  between	  imprinted	  loci	  and	  their	  methylation	  state	  (Fig	  5).	  No	  correlation	  between	  the	  methylation	  states	  of	  loci	  was	  identified,	  however	  when	  determining	  the	  Pearson's	  correlation	  for	  each	  locus,	  PLAGL1	  vs.	  IGF2R	  (Fig5A)	  for	  the	  H19	  LOM	  SRS	  population	  showed	  a	  significant	  correlation	  (r=	  0.49	  P	  value=	  0.03).	  Upon	  exclusion	  of	  the	  outlier	  (case	  SR18)	  no	  significant	  correlation	  (r=	  -­‐0.21	  P	  values=0.39)	  was	  calculated,	  indicating	  that	  case	  SR18	  skewed	  the	  data.	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Linking	  epimutations	  to	  phenotype	  Identification	  of	  the	  frequency	  of	  epimutations	  within	  the	  H19	  LOM	  and	  H19	  normal	  SRS	  populations	  was	  calculated	  	  (Fig	  6).	  Though	  no	  trend	  was	  apparent	  when	  comparing	  the	  frequency	  of	  GOM	  epimutations	  between	  the	  two	  SRS	  populations,	  investigation	  in	  to	  LOM	  (FIG	  6B)	  identified	  a	  possible	  trend.	  LOM	  at	  one	  or	  more	  additional	  loci	  (excluding	  H19)	  was	  significantly	  more	  frequent	  (Fisher	  exacts	  test	  P=0.03)	  in	  the	  population	  of	  SRS	  individuals	  that	  already	  had	  LOM	  at	  H19	  (33%	  of	  individuals	  tested),	  than	  those	  with	  normal	  methylation	  at	  
H19	  (4%	  of	  individuals	  tested	  had	  LOM	  at	  other	  loci).	  There	  was	  also	  one	  H19	  LOM	  SRS	  case	  (SRS18)	  presenting	  with	  LOM	  at	  3	  loci	  (GRB10,	  IGF2R	  and	  
PLAGL1),	  providing	  a	  strong	  case	  that	  epigenetic	  alterations	  at	  non-­‐11p15.5	  imprinted	  loci	  can	  influence	  the	  phenotype	  of	  patients.	  HM	  levels	  of	  individuals	  presenting	  with	  epimutations	  are	  presented	  in	  table	  4.	  
Comparison	  of	  clinical	  data	  of	  individuals	  with	  LOM	  at	  one	  locus	  identified	  no	  specific	  phenotype	  that	  could	  be	  attributed	  to	  the	  epimutations	  observed.	  This	  finding	  was	  also	  observed	  for	  cases	  with	  GOM	  epimutations.	  	  
Given	  the	  association	  with	  imprinting	  disorders	  and	  ART,	  conception	  method	  was	  then	  assessed	  in	  all	  cases	  with	  either	  LOM	  or	  GOM	  at	  one	  of	  the	  investigated	  loci.	  The	  results	  indicate	  that	  there	  was	  no	  association	  between	  methylation	  state	  and	  conception	  with	  only	  1	  case	  per	  methylation	  group	  being	  conceived	  via	  ART.	  	  
Cluster	  analysis	  was	  performed	  to	  identify	  any	  less	  apparent	  associations	  between	  methylation	  state	  and	  individuals.	  (Fig7)	  As	  H19	  was	  previously	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determined	  during	  diagnosis	  by	  alternative	  techniques,	  the	  exact	  methylation	  value	  is	  unknown	  and	  not	  included	  in	  the	  cluster	  analysis.	  This	  analysis	  highlighted	  3	  distinct	  groups.	  Group	  I	  consisted	  of	  n=7	  all	  of	  which	  fall	  within	  the	  
H19	  LOM	  SRS	  group.	  Group	  II	  consisted	  of	  n=28,	  Group	  III	  contained	  n=4,	  1	  of	  which	  was	  from	  H19	  LOM	  SRS	  population.	  This	  analysis	  suggests	  there	  maybe	  is	  some	  association	  between	  individuals,	  however	  phenotypical	  analysis	  of	  these	  groups	  does	  not	  yield	  any	  clear	  associations.	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Fig	  6:	  Frequency	  of	  epimutations	  in	  SRS	  normal	  and	  SRS	  H19	  LOM	  population.	  A)	  
Frequency	  of	  individuals	  presenting	  with	  LOM	  at	  loci	  other	  than	  H19.	  B)	  Frequency	  
of	  individuals	  presenting	  with	  GOM	  at	  loci	  other	  than	  H19.	  Fishers	  exact	  test	  
conducted	  to	  determine	  significance	  between	  the	  two	  SRS	  populations	  *=	  <	  0.05	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Table	  4:	  HM	  levels	  of	  individuals	  presenting	  with	  epimutations	  Pecentage	  of	  HM	  at	  loci	  Case	  
H19	  status	   PLAGL1	   GRB10	  	   GNAS	   PEG3	   SNRPN	   IGF2R	  SR6	   LOM	   50.00%	   31.44%	   50.00%	   N/A	   93.78%	   40.95%	  SR8	   LOM	   50.00%	   5.52%	   50.00%	   56.43%	   44.44%	   52.15%	  SR9	   LOM	   61.34%	   29.47%	   25.95%	   39.02%	   50.72%	   50.00%	  SR10	   LOM	   50.00%	   13.52%	   52.49%	   43.95%	   50.00%	   14.64%	  SR11	   LOM	   57.46%	   1.29%	   50.00%	   38.67%	   29.51%	   21.62%	  SR12	   LOM	   33.69%	   15.55%	   50.00%	   50.00%	   41.01%	   53.32%	  SR15	   LOM	   50.00%	   46.45%	   42.64%	   22.22%	   59.51%	   36.60%	  SR18	   LOM	   7.05%	   0.91%	   84.29%	   50.00%	   60.03%	   0.67%	  SR32	   Norm	   35.46%	   60.65%	   N/A	   44.20%	   54.06%	   67.23%	  SR34	   Norm	   48.35%	   50.00%	   N/A	   52.13%	   50.00%	   99.35%	  SR35	   Norm	   56.31%	   52.13%	   N/A	   33.58%	   50.00%	   60.38%	  
Percentage	  of	  HM	  for	  each	  investigated	  loci.	  Thershold	  for	  LOM	  or	  GOM	  was	  determinded	  values	  <2SD	  above	  or	  below	  the	  overal	  mean	  HM	  value.	  Bold	  red	  
text=	  LOM	  Bold	  Blue	  text=	  GOM	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   Fig	  7:	  Cluster	  analysis	  of	  all	  HM%	  obtained	  at	  GNAS,	  PEG3,	  GRB10,	  PLAGL1,	  
IGF2R,	  and	  SNRPN.	  Three	  main	  clusters	  are	  observed,	  with	  most	  individuals	  
residing	  in	  Group	  2.	  Group	  1	  and	  3	  could	  possibly	  indicate	  an	  alternative	  non	  
molecular	  association	  between	  the	  grouped	  individuals	  ,	  although	  no	  
phenotypical	  link	  had	  been	  observed.	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Discussion	  
The	  aim	  of	  this	  study	  was	  to	  investigate	  the	  association	  between	  SRS	  and	  methylation	  state	  at	  a	  selection	  of	  imprinted	  loci.	  The	  overall	  findings	  showed	  individuals	  with	  SRS	  are	  more	  susceptible	  to	  epimutations	  at	  imprinted	  loci	  other	  than	  H19	  compared	  to	  the	  control	  population.	  SRS	  individuals	  that	  present	  with	  H19	  LOM	  are	  also	  more	  likely	  to	  have	  LOM	  at	  other	  loci	  compared	  to	  SRS	  patients	  with	  normal	  IC1	  11p15.5	  methylation.	  
Findings	  and	  observations	  	  It	  was	  observed	  during	  this	  study	  that	  patients	  with	  LOM	  at	  the	  H19	  loci	  were	  more	  likely	  to	  present	  with	  more	  severe	  SRS	  phenotype,	  including	  increased	  prevalence	  of	  hemihypertrophy,	  prominent	  forehead,	  fifth	  figure	  clinodactyly	  and	  other	  abnormalities	  associated	  with	  SRS.	  This	  discovery	  is	  consistent	  with	  the	  findings	  of	  Bruce.S	  et	  al	  2009;	  Bartholdi	  D,	  et	  al	  2009	  and	  Wakeling	  EL	  et	  al	  2010,	  where	  the	  phenotypes	  of	  SRS	  patients	  idiopathic,	  UPD7(mat)	  and	  LOM	  H19	  were	  compared	  in	  larger	  cohorts	  (42	  confirmed	  SRS	  patients,	  201	  patients	  with	  suspected	  SRS	  and	  64	  confirmed	  SRS	  respectively).	  Bruce	  et	  al.	  additionally	  report	  that	  individuals	  with	  extreme	  H19	  LOM	  (<9%	  methylation)	  also	  presented	  with	  skeletal	  abnormalities	  (spinal	  problems)	  and	  genital	  defects.	  However	  for	  our	  study	  there	  was	  no	  clinical	  data	  about	  these	  abnormalities	  nor	  the	  degree	  of	  methylation	  of	  H19.	  Quantification	  of	  H19	  methylation	  would	  allow	  future	  investigation	  into	  whether	  extreme	  hypomethylathion	  of	  H19	  individuals	  is	  associated	  with	  increased	  LOM	  at	  other	  loci.	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This	  study	  identified	  the	  presence	  of	  either	  GOM	  or	  LOM	  epimutations	  at	  loci	  other	  than	  H19	  in	  12	  of	  the	  40	  (30%)	  SRS	  individuals.	  33%	  of	  patients	  with	  hypomethylation	  at	  H19	  loci	  presented	  with	  LOM	  at	  other	  imprinted	  loci	  compared	  to	  4%	  of	  patients	  with	  normal	  H19	  methylation.	  This	  corroborates	  the	  findings	  of	  Azzi	  at	  al.2009	  and	  Turner,	  CLS	  et	  al	  2010	  and	  where	  it	  was	  reported	  that	  individuals	  with	  H19	  LOM	  displayed	  multilocus	  methylation	  defects.	  However	  our	  study	  identified	  this	  to	  be	  a	  more	  common	  occurrence	  than	  Azzi	  et	  al.	  2009	  and	  Turner,	  CLS	  et	  al	  2010	  where	  it	  was	  reported	  that	  9.5%	  and	  17%	  (respectively)	  of	  individuals	  with	  H19	  LOM	  had	  LOM	  at	  least	  one	  other	  imprinted	  loci.	  However	  studies	  by	  Schönherr	  N	  et	  al,	  2007	  and	  Peñaherrera,	  M.	  et	  al	  2009,	  on	  32	  and	  35	  SRS	  patients	  respectively,	  provided	  no	  evidence	  of	  abnormal	  methylation	  at	  other	  imprinted	  loci.	  There	  was	  no	  association	  observed	  between	  phenotypes	  in	  individuals	  with	  LOM	  at	  multiple	  imprinted	  loci	  in	  our	  study,	  mirroring	  the	  results	  of	  Azzi.S	  et	  al	  2009.	  	  
Six	  imprinted	  loci	  were	  investigated	  in	  the	  study,	  PLAGL1,	  IGF2R,	  GRB10,	  PEG3,	  
SNRPN	  and	  GNAS.	  3	  SRS	  individuals	  with	  LOM	  and	  4	  with	  GOM	  at	  PLAGL1	  were	  identified;	  this	  result	  does	  not	  present	  a	  distinct	  conclusion	  being	  drawn	  as	  to	  the	  state	  of	  methylation	  in	  SRS.	  It	  has	  been	  shown	  that	  PLAGL1	  and	  GNAS	  are	  hypomethylated	  in	  several	  BWS	  patients,	  Bliek,	  J	  et	  al	  2009	  and	  therefore	  could	  potentially	  be	  affected	  in	  SRS,	  however	  a	  multiloci	  study	  on	  SRS	  patients	  did	  not	  yield	  any	  change	  in	  PLAGL1	  methylation.	  
One	  of	  the	  most	  interesting	  loci	  with	  aberrant	  methylation	  identified	  in	  this	  study	  was	  IGF2R,	  where	  2/18	  (11%)	  SRS	  with	  H19	  LOM	  demonstrated	  LOM	  at	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this	  locus.	  This	  is	  contradictory	  to	  a	  study	  by	  	  (Turner,	  CLS	  et	  al	  2010),	  where	  2/23	  H19	  LOM	  and	  5/56	  H19	  norm	  SRS	  paitents	  presented	  GOM	  at	  this	  loci.	  Th	  author	  hypothesised	  that	  GOM	  increased	  expression	  of	  IGF2R,	  which	  in	  turn	  decreases	  circulating	  IGF2	  and	  decreasing	  growth.	  However	  this	  study	  also	  identified	  1	  H19	  LOM	  SRS	  individual	  with	  LOM	  at	  IGF2R,	  while	  another	  in	  multi	  loci	  study,	  only	  identified	  LOM	  as	  the	  epimutation	  present	  at	  this	  locus	  (Azzi	  et	  al	  2009),	  which	  is	  consistent	  with	  the	  finding	  of	  the	  current	  study.	  As	  DNA	  methylation	  is	  normally	  associated	  with	  reduced	  gene	  expression,	  one	  would	  hypothesise	  that	  LOM	  at	  IGF2R	  would	  result	  in	  increased	  gene	  expression,	  and	  therefore	  decreased	  IGF2	  and	  subsequently	  reducing	  growth.	  OMIM	  (♯14728)	  summarised	  that	  loss	  of	  IGF2R	  in	  mice	  results	  in	  fetal	  over	  growth.	  
The	  other	  finding	  was	  LOM	  at	  the	  GRB10	  locus	  in	  3/17	  H19	  LOM.	  Though	  there	  were	  a	  few	  individuals	  in	  the	  control	  population	  that	  expressed	  a	  slight	  decrease	  in	  methylation,	  this	  degree	  of	  LOM	  was	  not	  as	  strong	  as	  that	  observed	  in	  the	  17%	  of	  SRS	  H19	  LOM	  mentioned.	  LOM	  was	  also	  observed	  in	  one	  individual	  involved	  the	  multi	  loci	  study	  performed	  by	  Turner,	  CLS	  et	  al	  2010,	  however	  this	  study	  did	  not	  expand	  on	  the	  finding,	  and	  instead	  concluded	  that	  epimutations	  at	  candidate	  imprinted	  genes	  MEST/PEG1,	  GRB10	  and	  PEG10	  on	  Chromosome	  7	  may	  not	  lead	  to	  an	  SRS	  phenotype.	  LOM	  at	  this	  locus	  would	  also	  result	  in	  increased	  gene	  expression.	  A	  previous	  study	  on	  mice	  identified	  that	  maternal	  over	  expression	  of	  
GRB10	  (which	  also	  is	  observed	  in	  UPD7	  (mat)	  SRS)	  resulted	  in	  growth	  retardation	  (Shiura	  H	  et	  al	  2009)	  whereas	  loss	  of	  GRB10	  results	  in	  fetal	  overgrowth	  (Abu-­‐Amero,	  S	  et	  al	  2010).	  Thus	  the	  findings	  of	  this	  study	  suggests	  that	  epimutations	  at	  loci	  such	  as	  GRB10	  may	  play	  a	  role	  in	  SRS.	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Current	  research	  Research	  in	  the	  field	  of	  SRS,	  has	  significantly	  increased	  in	  recent	  years,	  with	  attentions	  focused	  on	  the	  molecular	  basis	  for	  the	  syndrome	  and	  understanding	  idiopathic	  SRS.	  As	  previously	  mentioned	  several	  studies	  have	  also	  looked	  at	  methylation	  at	  other	  imprinted	  loci	  including	  Peg1/	  MEST,	  PEG10,	  IGF2PO	  and	  DLK	  (Turner,	  CLS	  et	  al	  2010;	  Peñaherrera,	  M.	  et	  al	  2009;	  Azzi	  et	  al	  2009).	  Findings	  within	  this	  field	  have	  shown	  that	  LOM	  at	  other	  imprinted	  loci	  are	  not	  as	  common	  as	  one	  might	  have	  first	  hypothesised,	  and	  do	  not	  appear	  to	  affect	  phenotype,	  leaving	  many	  questions	  still	  unanswered.	  	  
Other	  studies	  have	  investigated	  mutations	  in	  candidate	  genes	  as	  possible	  causes	  of	  SRS.	  Jager.	  S	  et	  al	  2009	  focused	  on	  mutations	  in	  PLAGL1	  while	  Eaggermann,	  T	  et	  al	  predominantly	  focused	  on	  GNAS.	  Neither	  study	  found	  any	  point	  mutation	  or	  copy	  number	  variable	  (CNV)	  that	  could	  be	  attributed	  to	  SRS.	  Other	  investigations	  have	  focused	  on	  looking	  for	  mutations,	  deletions	  or	  rearrangements	  around	  the	  
H19	  locus.	  A	  preliminary	  study	  by	  Grønskov	  K	  et	  al	  2011	  of	  4	  patients	  with	  suspected	  SRS,	  identified	  breakpoints	  and	  disruptions	  of	  the	  shared	  H19/IGF2	  enhancer	  region,	  in	  all	  individuals.	  Demars,	  J	  et	  al	  2011	  also	  identified	  a	  novel	  duplication	  in	  part	  of	  H19/IGF2	  imprinting	  control,	  which	  resulted	  in	  a	  SRS	  phenotype	  only	  if	  maternally	  inherited	  when	  investigating	  SNPs	  within	  the	  11q15	  imprinted	  region	  in	  72	  SRS	  patients	  who	  displayed	  LOM	  at	  ICR1.	  While	  Adkins	  RM	  et	  al	  2010,	  identified	  a	  SNP	  near	  the	  CTCF	  binding	  site,	  which	  has	  been	  associated	  with	  birth	  weight.	  These	  studies	  highlight	  the	  need	  to	  examine	  not	  only	  the	  enhancer	  and	  regulatory	  regions	  of	  imprinted	  genes	  but	  also	  promoter-­‐enhancer	  interactions	  in	  individuals	  with	  imprinting	  defects.	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Genome	  wide	  searches	  for	  SNPs	  and	  microdeletions	  have	  also	  been	  conducted	  to	  pinpoint	  candidate	  regions	  or	  genes	  associated	  with	  SRS.	  In	  the	  case	  of	  Lyn,	  SY	  et	  al	  2010,	  a	  study	  on	  34	  SRS	  individuals	  highlighted	  five	  microdeletions	  in	  14.7%	  of	  the	  population	  tested,	  though	  further	  investigation	  has	  yet	  to	  be	  carried	  out	  to	  determine	  any	  link	  with	  SRS.	  
In	  an	  attempt	  to	  further	  understand	  SRS,	  other	  groups	  have	  begun	  investigating	  the	  proteins	  involved	  in	  silencing	  gene	  expression	  via	  DNA	  methylation,	  such	  as	  methyl-­‐CpG	  binding	  (MBD)	  proteins	  that	  preferentially	  bind	  to	  methylated	  DNA	  and	  facilitate	  recruitment	  of	  other	  transcription	  repressive	  proteins	  such	  as	  histone	  deacetylases.	  In	  mice	  reduced	  levels	  of	  MBD3	  resulted	  in	  LOM	  at	  the	  ICR1	  (H19),	  thus	  providing	  a	  candidate	  protein	  for	  SRS.	  However	  Bachmann	  et	  al	  2009	  have	  since	  identified	  that	  mutations	  in	  MBD3	  are	  not	  responsible	  of	  the	  LOM	  at	  H19	  that	  is	  so	  frequently	  observed	  in	  SRS.	  Other	  groups	  have	  begun	  to	  investigate	  if	  the	  intrauterine	  environment	  attributes	  to	  SRS,	  reporting	  that	  hypomethylation	  at	  H19	  has	  been	  found	  in	  the	  placentas	  of	  pregnancies	  associated	  with	  fetal	  growth	  restriction	  (Banister,	  CE.	  Et	  al	  2011;	  Koukoura,	  O.	  et	  a	  2011).	  	  
Ongoing	  research	  highlights	  the	  complexity	  of	  SRS	  with	  many	  factors	  affecting	  the	  phenotype.	  Studies	  such	  as	  the	  current	  report	  are	  important	  to	  progress	  the	  understanding	  of	  this	  multifactorial	  syndrome.	  .	  
Limitations	  of	  this	  study	  Investigation	  of	  methylation	  state	  at	  imprinted	  loci	  using	  BA	  biosciences	  EpiTect	  Methyl	  Profiler	  is	  a	  relatively	  novel	  technique,	  with	  this	  assay	  predominantly	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being	  used	  for	  cancer	  methylation	  analysis.	  It	  claims	  to	  produce	  results	  comparable	  to	  bisulfite	  sequencing	  and	  permits	  the	  analysis	  of	  multiple	  samples	  or	  genes	  at	  one	  time	  and	  could	  have	  huge	  potential	  in	  semi	  high-­‐throughput	  analysis	  of	  methylation	  states	  (SA	  Bioscience	  methylation	  flyer).	  http://www.sabiosciences.com/manuals/Methyl_FLYER_lo.pdf	  
Nevertheless	  the	  GOM	  or	  LOM	  results	  obtained	  in	  this	  study	  should	  be	  confirmed	  by	  a	  widely	  accepted	  method	  such	  as	  methylation	  specific	  PCR	  or	  bisulphate	  sequencing.	  One	  sample	  included	  in	  this	  study	  (SR18)	  had	  already	  had	  the	  methylation	  state	  of	  several	  loci	  previously	  tested	  via	  the	  above-­‐mentioned	  techniques.	  The	  results	  of	  these	  investigations	  produced	  the	  same	  conclusions	  for	  this	  individual	  as	  using	  the	  EpiTect	  Methyl	  Profiler,	  indicating	  that	  this	  method	  is	  likely	  to	  be	  reliable	  and	  provide	  accurate	  results.	  
Another	  limitation	  with	  this	  study	  was	  the	  number	  of	  loci	  tested;	  
www.geneimprint.com	  published	  a	  list	  of	  known	  and	  predicted	  imprinted	  loci	  in	  humans.	  Although	  the	  loci	  investigated	  here	  were	  selected	  for	  their	  potential	  involvement	  in	  SRS,	  many	  more	  have	  yet	  to	  be	  studied	  in	  relation	  to	  SRS.	  
Though	  a	  reasonable	  size	  cohort	  was	  used,	  larger	  studies	  have	  been	  conducted,	  allowing	  for	  the	  identification	  of	  rare	  events	  and	  allowing	  more	  accurate	  quantification,	  of	  any	  observation	  made.	  	  
The	  most	  common	  method	  for	  molecular	  diagnosis	  of	  SRS,	  is	  by	  examining	  lymphocyte	  DNA,	  therefore	  most	  DNA	  used	  in	  this	  study	  is	  derived	  from	  patients	  lymphocytes,	  however	  many	  reports	  have	  been	  conducted	  in	  both	  BWS	  and	  SRS	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patients,	  highlighting	  the	  presence	  of	  imprinting	  mosaicism,	  (Peñaherrera,	  M.	  et	  al	  2009)	  with	  differences	  in	  hypomethylation	  even	  being	  observed	  between	  different	  sides	  of	  the	  oral	  cavity	  in	  one	  individual	  (Begemann,	  M	  et	  al	  2010).	  This	  phenomenon	  could	  potentially	  result	  in	  cases	  being	  misdiagnosed,	  and	  methylation	  abnormalities	  being	  missed.	  	  
Future	  directions	  It	  is	  clear	  that	  we	  are	  still	  a	  long	  way	  off	  from	  determining	  the	  molecular	  causes	  behind	  SRS,	  and	  that	  much	  more	  research	  needs	  to	  be	  done;	  it	  is	  therefore	  proposed	  that	  future	  work	  should	  be	  focused	  on	  obtaining	  quantitive	  high	  throughput	  methylation	  profiles	  of	  CpG	  islands	  in	  SRS	  via	  techniques	  such	  as	  Illumina	  methylation	  assays,	  and	  within	  5	  years,	  the	  cost	  of	  whole	  genome	  bisulfite	  sequencing	  should	  be	  comparable	  to	  allow	  whole	  genome	  methylation	  analysis.	  Comparing	  methylation	  states	  of	  multiple	  loci,	  imprinted	  or	  not	  in	  long	  non	  coding	  regions	  of	  large	  cohorts	  of	  SRS	  patients	  (including	  H19	  LOM,	  UPD7	  (mat)	  and	  idiopathic	  patients)	  to	  control	  populations	  (both	  normal	  gestational	  size,	  and	  small	  gestation	  age	  non-­‐SRS	  individuals)	  novel	  epimutions	  and	  regulatory	  regions	  in	  non	  coding	  DNA	  may	  be	  identified.	  However	  this	  type	  of	  study	  is	  currently	  limited	  by	  economical	  constraints	  .	  In	  depth	  clinical	  data	  for	  all	  participants	  of	  future	  studies	  should	  also	  be	  acquired	  where	  possible	  allowing	  epigenotype/	  phenotype	  comparisons.	  Analysis	  the	  methylation	  of	  several	  different	  tissues	  per	  individual,	  for	  example,	  leukocytes	  and	  buccal	  swab	  DNA	  should	  also	  be	  included	  in	  future	  studies.	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In	  conclusion,	  this	  study	  identifies	  that	  aberrant	  methylation	  at	  loci	  other	  than	  
H19,	  is	  more	  common	  in	  SRS	  suffers	  that	  already	  present	  with	  LOM	  at	  H19,	  although	  this	  observation	  is	  only	  present	  in	  33%	  of	  H19	  SRS	  individuals.	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Appendix	  1:	  Clinical	  data	  for	  individual	  SRS	  cases	  












Other	  clinical	  clinical	  features	  









Right	  arm	  and	  leg	  
hemihypertrophy,	  prominent	  
forehead,	  down	  turned	  mouth	  








Right	  leg	  hemihypertrophy,	  
facial	  asymmetry,	  prominent	  
forehead,	  micrognathia	  and	  
fifth	  finger	  clinodactyly	  









café	  au	  lait	  
patches	  
Mild	  facial	  asymmetry,	  down	  
turned	  mouth,	  fifth	  finger	  
clinodactyly	  ,short	  rightfifth	  
finger,	  mild	  left	  ptosis	  and	  
anteverted	  ears.	  
SR04	   LOM	  








Face,	  arm	  ,	  leg	  and	  trunk	  
hemihypertrophy,	  facial	  
asymmetry	  and	  prominent	  
forehead.	  









Right	  leg	  hemihypertrophy,	  
facial	  asymmetry,	  prominent	  
forehead,	  mild	  micrognathia	  
and	  fifth	  finger	  clinodactyly	  










Prominent	  forhead,	  down	  
turned	  mouth	  fifth	  finger	  
clinodactyly	  and	  stork	  mark	  on	  
nape	  of	  neck	  











Left	  hemihypertrophy,	  mild	  
facial	  asymmetry,	  prominent	  
forehead	  and	  dental	  crowding	  









Left	  leg	  hemihypertrophy,	  
prominent	  forehead	  and	  fifth	  
finger	  clinodactyly	  















forehead,	  down	  turned	  
mouth,	  fifth	  finger	  
clinodactyly	  and	  
camptodactyly	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Delayed	  bone	  age,	  facial	  
asymmetry,	  prominent	  
forehead,	  down	  turned	  
mouth,	  micrognathia,	  fifth	  
finger	  clinodactyly	  and	  Patent	  
ductus	  arteriosus	  (PDA)	  









Mild	  delayed	  bone	  age,	  
prominent	  forehead,	  down	  
turned	  mouth,	  micrognathia	  
and	  fifth	  finger	  clinodactyly	  








Facial	  asymmetry,	  prominent	  
forehead,	  down	  turned	  
mouthand	  fifth	  finger	  
clinodactyly	  
SR13	   LOM	  











Leg	  hemihypertrophy,	  delayed	  
bone	  age,	  prominent	  
forehead,	  down	  turned	  
mouth,	  fifth	  fingure	  
clinodactyly,	  slight	  deepset	  
eyes	  and	  trivial	  PDA	  







Prominent	  forhead,	  down	  
turned	  mouth,	  fifth	  finger	  
clinodactyly	  and	  
camptodactyly	  













Right	  side	  hemihypertrophy,	  
prominent	  forehead,	  down	  
turned	  mouth,	  micrognathia,	  
fifth	  finger	  clinodactyly	  









prominent	  forehead,	  down	  
turned	  mouth,	  fifth	  fingure	  
clinodactyly.	  











Left	  arm	  and	  leg	  
hemihypertrophy,	  prominent	  
forehead	  and	  fifth	  finger	  
clinodactyly	  
SR18	   LOM	   ICSI conception 
At	  	  2yr	  3	  months;	  typical	  BWS	  phenotype	  with	  overgrowth	  (postnatal	  
onset),	  macroglossia,	  abnormal	  umbilicus,	  ear	  lobe	  creases	  and	  
asymmetry	  and	  other	  features.	  Fits	  criteria	  for	  BWS	  clinical	  
diagnosis.	  Other	  atypical	  features;	  unsteady	  gait	  and	  facial	  
phenotype	  (simular	  to	  AS/PWS)	  Molecular	  info:	  SNRPN	  methylation	  
normal	  LOM	  H19	  PLAGL1	  and	  MEST	  
SR19	   Normal	  






Delayed	  bone	  age	  









Facial	  asymmetry	  and	  
prominent	  forehead	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left	  arm	  hemihypertrophy,	  
prominent	  forehead,	  down	  
turned	  mouth	  congenital	  
cardiac	  malformations	  and	  
low	  set	  ear	  on	  Right	  














Flat	  philtrum,	  full	  cheeks	  and	  
congenital	  cardiac	  
malformations	  












forehead,	  down	  turned	  mouth	  
and	  fifth	  finger	  clinodactyly	  











right	  thorax	  and	  left	  leg	  
hemihypertrophy,	  facial	  
asymmetry,	  down	  turned	  
mouth,	  fifth	  finger	  
clinodactyly,	  short	  broad	  neck	  
and	  congenital	  cardiac	  
malformations	  






















Delayed	  bone	  growth,	  
prominent	  forehead,up	  
turned	  Nose,	  frontal	  cowslick	  
to	  hair	  and	  gingiva.	  



























Mild	  face	  hypoplasia,	  small	  
upturned	  nose,	  thin	  lip	  










abnormal	  crease	  left	  palm	  
	   94	  











Delayed	  bone	  age	  and	  fifth	  
finger	  clinodactyly	  











au	  lait	  patches	  
Delayed	  bone	  age	  












Prominent	  forehead	  and	  ears	  
and	  triangular	  face	  











Low	  set	  ears	  and	  fifth	  finger	  
clinodactyly	  









au	  lait	  patches	  
Facial	  asymmetry,	  prominent	  
forehead,	  down	  turned	  mouth	  
and	  fifth	  finger	  clinodactyly	  










Right	  leg	  hermihypertrophy,	  
prominent	  forehead	  and	  fifth	  
finger	  clinodactyly	  











Prominent	  forehead	  and	  
down	  turned	  mouth	  








left	  hand	  and	  leg	  
hemihypertrophy,	  delayed	  
bone	  age,	  prominent	  forehead	  
and	  fifth	  finger	  clinodactyly	  
SR40	   Normal	  








Right	  leg	  hermihypertrophy,	  
prominent	  forehead	  and	  fifth	  
finger	  clinodactyly	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